Thirty-First Annual Meeting and Scientific Sessions
April 13 - 16, 2011

ISHLT Academy: Core Competencies in Lung Transplantation
April 12 - 13, 2011

In this booklet:

Annual Meeting • Call For Abstracts 2
Daily Schedule • At A Glance 8
Annual Meeting • Scientific Program 20
ISHLT Academy • Scientific Program 37
Registration And Housing Forms 41
Dear Colleagues,

On behalf of John Dark, M D, ISHLT’s President, and the ISHLT Board of Directors, it is my great honor and personal pleasure to invite you to participate in the 31st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation, which will be held April 13-16, 2011 in the beautiful city of San Diego.

The 2010 meeting in Chicago was an exciting and superb Congress which – in spite of epic volcanic interference – was attended by more than 1800 delegates. The program kicked off with Satellite Symposia early on Wednesday morning and wrapped up with an entertaining debate mid-day Saturday. The first ISHLT Academy ran from Saturday afternoon through mid-day Sunday and was fully subscribed and very highly rated. The 2011 meeting will follow a similar format, with the ISHLT Academy devoted to Pulmonary Transplantation running from Tuesday afternoon into Wednesday morning, Pre-Meeting Symposia all day Wednesday, and three full days of Plenary, Concurrent Abstract and Sunrise and Mid-Day Symposium sessions from Thursday through Saturday.

Our Society's Annual Meeting provides a collegial, interactive forum for evaluating evolving approaches to patient care based on transplantation and emerging alternatives. As we conclude our celebration of the Society’s 30th year, a major theme of the San Diego Annual Meeting will continue to be “Joint Action.” While sub-specialization is prominent in our field, as in all of medicine, ISHLT promotes close interdisciplinary collaboration between the diverse scientists and clinicians who participate in the care and study of patients with end-stage heart and lung failure. Indeed our Annual Meeting’s main goal is to provide continuing education and interdisciplinary interaction as the basis for further improvements in both survival and quality of life for our patients. The San Diego meeting will sustain popular recent programming innovations, including Invited Keynote and Pioneer Lectures, Featured Abstracts and Late-breaking Clinical Trials.

In addition, the theme “Joint Action” also extends beyond cooperation within and between the teams of current established practitioners to include the training of our junior members. To support our mentoring mission, the San Diego Annual Meeting will again feature Symposia and lunch-time sessions geared specifically to Residents and Fellows, as well as formal educational curricula through the new ISHLT Academy program focused this year on early career lung transplant professionals (starting Tuesday, prior to the meeting).

In the workings of the Society, ISHLT's Scientific Councils and Committees have been given increasing importance as a forum for the development of international consensus documents, for support of clinical research consortia and as a source for much of the Annual Meeting's educational content. In recognition of their key and expanding roles, Council meetings have been scheduled at noon Wednesday and early Wednesday and Thursday evenings, with minimal competition from the scientific program. We have also minimized conflicts between popular Councils or Committees where we know that the interests of our members overlap.

ISHLT will host a Welcome/Exhibit Hall Opening Reception in the Exhibit Hall on Wednesday evening, April 11. The Gala Reception on Friday night at the Hilton San Diego Bayfront, the primary meeting hotel, will overlook beautiful San Diego Harbor and will include cocktails, heavy hors d'oeuvres and dancing as the social highlight of the meeting. As our 30th Anniversary year concludes, a special recognition ceremony may be expected!

The presentation by our members of your high quality, cutting-edge scientific work marks the ongoing progress in our field, and, in addition to the lovely venue, is a primary attraction of the meeting for our members. As in the past, abstracts will only be accepted on-line, using our convenient and user-friendly web-based platform. Please note that this year the abstract submission deadline is November 19 at 11:59 pm Eastern Standard (North America) Time. This delayed deadline, two months later than in prior years, is enabled by improving review technology and will allow the scientific content of the Concurrent Sessions to be as current and educationally relevant as possible. Please follow closely the instructions for abstract submission, which are outlined on the submission web-site, which can be accessed from the ISHLT web site (www.ishlt.org). We particularly encourage the submission of work by your trainees and young investigators; the best of their work will continue to be highlighted in the Caves' Award competition.

We look forward to welcoming you in the exciting city of San Diego as we convene the 31st ISHLT Annual Meeting and Scientific Sessions!

Best regards,

Richard N. Pierson III, M D
ISHLT 2011 Scientific Program Chair
The Abstract Submission Program will be live on the ISHLT web site (www.ishlt.org) beginning August 23, 2010. The deadline for receipt of abstracts is November 19.

YOU MAY SUBMIT YOUR ABSTRACT IN ONE OF THE FOLLOWING CATEGORIES:

- Basic Science
- Case Reports (for Junior Faculty only)
- Cell Transplantation/Tissue Engineering
- Clinical Heart Transplantation
- Clinical Lung/Heart-Lung Transplantation
- Donor Management, Organ Preservation, Organ Allocation
- Health Economics
- Immunobiology
- Immunosuppression – Animal Studies
- Immunosuppression – Clinical Studies
- Infectious Diseases – Heart
- Infectious Diseases – Lung
- Late Breaking Clinical Trials
- Mechanical Circulatory Support
- Medical Management of Heart Failure and Candidate Selection
- Medical Management of Lung Failure and Candidate Selection
- Novel/Alternative Therapies to Transplantation
- Nursing Sciences
- Pathology
- Pediatrics – Heart
- Pediatrics – Lung
- Post Transplant Complications – Heart
- Post Transplant Complications – Lung
- Pulmonary Hypertension
- Quality of Life
- Social Sciences
- Xenotransplantation

ABSTRACT CONTENT SHOULD INCLUDE:
- a. Brief statement of purpose of the study (goal or hypothesis being tested)
- b. Statement of methods and procedures used
- c. Summary of results, presented in sufficient detail to support the conclusion
- d. Conclusion

Accepted abstracts will be published in the April 2011 supplement to the Journal of Heart and Lung Transplantation.

Authors whose papers are selected for presentation at the meeting will be notified in January 2011.

Submitted abstracts will not be considered for presentation if they will be published as an article prior to April 16, 2011.

INFORMED CONSENT AND ETHICAL STANDARDS: Any studies involving human subjects or the use of human tissue must conform to the principles of the Declaration of Helsinki (http://www.wma.net/en/30publications/10policies/b3/index.html), must adhere to the principles of the ISHLT Statement on Transplant Ethics (http://www.ishlt.org) and must meet the informed consent requirements of the institution and country in which the study was performed.
USE OF ANIMALS: Submission of studies involving the use of animals implies that their use conforms fully with current NIH, EU, or analogous national guidelines for the care and use of animals.

PHARMACEUTICAL FUNDING: If the research was partially or fully funded by a proprietary organization (i.e., a pharmaceutical or device manufacturer), this information and the name of the funding company must be stated at the end of the abstract.

For purposes of blind scoring, institutional names must be omitted whenever possible in the title and body of the abstract.

CONTENT VALIDITY AND FAIR BALANCE: Authors are required to prepare fair and balanced presentations that are objective and scientifically rigorous. All the recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection and analysis.

UNLABELED AND UNAPPROVED USES: Abstracts that include information in whole or in part related to non-FDA approved uses for drug products and/or devices must clearly state the unlabeled indications or the investigational nature of their proposed uses in the body of the abstract.

USE OF GENERIC VERSUS TRADE NAMES: Abstracts must use scientific or generic names when referring to products. Should it be necessary to use a trade name, then the trade names of all similar products or those within a class must be used.

COMMERCIAL INFLUENCE: Abstract presenters are not permitted to receive any travel, hotel or registration stipends or other financial assistance related to the ISHLT 2011 Annual Meeting from any company whose products or class of products are discussed in the abstracts.

Abstract authors may not receive direct input regarding the content of the abstract/presentation from any company whose products or class of products are discussed in the abstract. Employees of a commercial interest are generally not permitted to serve as the first author, presenting author, senior author or corresponding author of an abstract. In rare circumstances where the work does not involve any academic collaborators, exceptions to this policy MAY be considered on a case by case basis. After all abstracts have been selected for presentation, ISHLT will initiate this process by communicating with the corresponding author of any abstracts which list an industry employee as first author, presenting author, senior author or corresponding author of an abstract.

CONFLICT OF INTEREST DISCLOSURE: Disclosure of all relevant financial relationships is required by all abstract authors. Full and complete disclosure for EVERY author must be submitted with the abstract. It is the responsibility of the individual submitting the abstract to obtain and provide disclosure information for each author listed on an abstract. Each individual author is responsible for the accuracy and completeness of the disclosure information submitted on his/her behalf.

If no relevant financial relationships exist, this must be stated. Failure to provide complete disclosure information will result in disqualification from participation in the educational activity. This requirement is intended neither to imply any impropriety of such relationships nor to prejudice any individual planner, presenter or author. It is merely to identify such relationships through full disclosure and to allow ISHLT to assess and resolve potential influences on the educational activity prior to the planning and implementation of an educational activity.

Definitions:

FINANCIAL RELATIONSHIPS: Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, stipends, honoraria, gifts, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership and other activities from which remuneration is received or expected, including subsidized travel, hotel and registration fees for any activities. ‘Contracted research’ refers to research funding in which an institution a grant and manages the grant funds and an individual is the principal or named investigator on the grant at that institution.

RELEVANT FINANCIAL RELATIONSHIPS: Relevant financial relationships are those in which an individual (including the individual’s spouse/domestic partner/business partner) has/had any of the above mentioned financial relationships, in any amount, occurring presently or within the last 12 months with a commercial entity producing health care goods or services.

CONFLICT OF INTEREST: Circumstances create a potential conflict of interest when an individual has an opportunity to affect educational content related to the products or services of a commercial interest with which he/she has a financial relationship.

COMMERCIAL ENTITY: Any proprietary entity developing, producing, marketing or selling health care goods and services, with the exception of non-profit or government organizations.
Late Breaking Clinical Trial Submissions

To assure that truly “late breaking” information is included in the meeting, authors may submit abstracts to this category describing those trials and studies that are not yet completed as of November 19, 2010.

Studies which have results and conclusions available by November 19, 2010 may not submit their abstracts in the late breaking clinical trials category.

This abstract category is intended to provide a forum for the presentation of high impact multi-center studies or particularly provocative single center investigations. In general, such studies would include prospective, randomized trials that seek to investigate new approaches to the diagnosis and/or treatment of cardiothoracic diseases relevant to the field and that have the potential to alter our contemporary treatment paradigm. Final selection of presentations will be made by a panel of reviewers on behalf of the program committee.

Final analysis of the trial results and conclusions MUST be submitted to Lisa Edwards at the ISHLT headquarters by March 18th, 2011. This analysis will be seen only by a closed panel to ensure complete confidentiality of the results prior to presentation.

A trial accepted for presentation cannot be withdrawn from presentation simply because the results do not conform to expectations.

The program committee chair, in consultation with the program committee, reserves the final decision regarding assignment of presentations to the Late Breaking abstract session.

If you would like to have a late breaking clinical trial considered for this session, please provide the following information in your abstract:

- Title of the study
- Sponsor of the trial, if any
- Completion date of the trial
- Summary of objectives
- Methods
- Endpoints

Please use the standard online abstract submission process to submit an abstract in this category. The abstract submitted for the November 19th deadline will serve as a placeholder for the final abstract.

Note: Abstracts for the meeting will be published in the April supplement to the Journal of Heart and Lung Transplantation. If you wish to have your trial results published as an abstract in this supplement, ISHLT MUST receive a revised version of the abstract reflecting the study findings no later than January 5, 2011.
**Abstract Awards**

**PHILIP K. CAVES AWARD**

This award is named for Philip K. Caves, who developed and pioneered the technique of transvenous endomyocardial biopsy for use in the monitoring of cardiac graft tolerance. Established in 1982 to encourage and reward original research in transplantation performed by residents, fellows and graduate students, this $1,000 award is bestowed annually on the resident/fellow/student whose oral presentation is judged to be the best at the Annual Scientific Meeting. **Residents/Fellows who are first authors and presenters** may elect to have their abstracts considered for the Caves Award. Candidates for the Caves Award must be current members of the Society or be working under a current member of the Society. The online submission process includes an area to indicate that you wish to have your abstract considered for this award. The award will be presented at the Society’s Plenary Session. Anyone who has previously won the award is not eligible to apply.

**NURSING AND SOCIAL SCIENCE EXCELLENCE IN RESEARCH AWARD**

This award was established in 2005 to recognize excellence in Nursing and Social Science research, with the purpose of encouraging original investigation and professional excellence in the preparation of scientific papers. This award recognizes an outstanding contribution by a nurse or social scientist whose work makes an important contribution to the field of heart and lung transplantation. This $1,000 award is bestowed annually on the nurse or social scientist whose oral presentation is judged to be the best at the Annual Scientific Meeting. **Nurses and social scientists who are first authors and presenters** may elect to have their abstracts considered for this award. The award will be presented at the Society’s Plenary Session. Anyone who has previously won the award is not eligible to apply.

**BRANISLAV RADOVANCEVIC MEMORIAL BEST MCS ABSTRACT AWARD**

Established in 2009, the Branislav Radovancevic Memorial Best MCS Abstract Award is a $2500 travel award to the ISHLT Annual Meeting designed to encourage submission of high quality abstracts in the mechanical circulatory support category, particularly from individuals in emerging countries. The goal of the award is to encourage scholarly clinical work in MCS in emerging countries and to facilitate scientific exchange regarding MCS. Dr. Radovancevic, a long-time member of ISHLT, was devoted to the encouragement of scientific collaboration with Eastern European physicians and scientists. This awards are designed to encourage others to continue his efforts to develop MCS and provide mentorship to others. Therefore, priority will be given to researchers and clinicians who are residents or fellows, and/or who are from emerging countries. **Individuals who are first authors and presenters** may elect to have their abstracts considered for this award. Candidates for the award must be current members of the Society. The online submission process includes an area to indicate that you wish to have your abstract considered for this award. The award will be presented at the Society’s Plenary Session. Anyone who has previously won the award is not eligible to apply.
ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 2700 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

The Purposes of the Society are:

- To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease, and related sciences.
- To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.
- To hold scientific meetings featuring presentations and discussions relevant to these disciplines.
- To sponsor a scientific journal for the publication of manuscripts related to these disciplines.
- To establish and maintain an international registry for heart and lung transplantation.
- To award research grants and establish endowments for the study of these disciplines.
San Diego enjoys beautiful weather year round with an average daily temperature of 70.5°F (21.4 degrees Celsius) in April.

San Diego boasts a citywide population of nearly 1.3 million residents and more than 3 million residents in San Diego County. Within its 4,200 sq. miles, San Diego County encompasses 18 incorporated cities and numerous other charming neighborhoods and communities, including downtown’s historic Gaslamp Quarter, Little Italy, Coronado, La Jolla, Del Mar, Carlsbad, Escondido, La Mesa, Hillcrest, Barrio Logan and Chula Vista just to name a few. San Diego is renowned for its idyllic climate, 70 miles of pristine beaches and a dazzling array of world-class family attractions. Popular attractions include the world-famous San Diego Zoo and Wild Animal Park, Sea World San Diego and LEGOLAND California. San Diego offers an expansive variety of things to see and do, appealing to guests of all ages from around the world.

In San Diego’s East County, the terrain varies from gentle foothills to mile-high mountains and the historic mining town, Julian, down to the 600,000-acre Anza Borrego Desert State Park, offering nature-conscious visitors endless opportunities to hike, camp, fish, observe wildlife and much more. In San Diego’s North County, the agricultural community produces quantities of flowers and magnificent produce. Wine growers are also making a mark by growing and harvesting quality grapes that become excellent wines, which are served at some of the most elegant restaurants and resorts in the region. Along the west, 70 miles of Pacific Ocean coastline not only supports year-round outdoor recreation, such as surfing, boating, sailing and swimming, but also important scientific research at the Scripps Institution of Oceanography. To the south, it’s a whole different country, Mexico, featuring its own cultural offerings in various towns along the border and coastline, including Tijuana, Rosarito and Ensenada.

San Diego’s arts and culture and culinary arts are booming. The hottest, new culinary arts talents prepare award-winning meals throughout the regions 6,400 eating establishments. Balboa Park, the largest urban cultural park in the U.S., is home to 15 museums, numerous art galleries, beautiful gardens, the Tony Award-winning The Globe Theatres and the world-famous San Diego Zoo.

San Diego County also features 92 golf courses and a variety of exciting participatory and spectator sports, beachfront resorts and luxury spas, gaming, a dynamic downtown district, annual special events and unique holiday offerings, multicultural festivals and celebrations, colorful neighborhoods and communities, a rich military history and much more.

For more information on the great city of San Diego, please visit the San Diego Convention & Visitors Bureau link below.

http://wikitravel.org/en/San_Diego
(quick overview)

www.sandiego.org/nav/Visitors
(convention and visitor’s bureau site)

www.lonelyplanet.com/usa/san-diego
(travel guide site)

www.frommers.com/destinations/sandiego/
(travel guide site)
<table>
<thead>
<tr>
<th>Time</th>
<th>SAPPHIRE IM</th>
<th>INDIGO &amp; Foyer</th>
<th>SAPPHIRE FOYER</th>
<th>SAPPHIRE 410</th>
<th>INDIGO 204A</th>
<th>INDIGO 201B</th>
<th>SAPPHIRE 400</th>
<th>INDIGO 206</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>PRE-MTG SYMP 1</td>
<td>PRE-MTG SYMP 2</td>
<td>PRE-MTG SYMP 3</td>
<td>MASTERS ACADEMY</td>
<td>PRE-MTG SYMP 4</td>
<td>Nursing Pros, Soltri</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 am</td>
<td>Heart - Risk Scores</td>
<td>Lung Microvascular</td>
<td>Lung Allocation</td>
<td>MASTERS ACADEMY 7:30 am - 10:00 am</td>
<td>PRE-MTG SYMP 8</td>
<td>LungTx ECMO BM</td>
<td>PRE-MTG SYMP 9</td>
<td>ID CMV Storm</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Lunch Break</td>
<td>Lunch Break</td>
<td>Lunch Break</td>
<td>Lunch Break</td>
<td>Pul Tx Council</td>
<td>Pen Tx Council</td>
<td>Pul Tx Council</td>
<td>Pul Tx Council</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>PRE-MTG SYMP 10</td>
<td>PRE-MTG SYMP 11</td>
<td>PRE-MTG SYMP 12</td>
<td>PRE-MTG SYMP 13</td>
<td>PRE-MTG SYMP 14</td>
<td>Kids on Waitlist</td>
<td>PRE-MTG SYMP 15</td>
<td>COL</td>
</tr>
<tr>
<td>10:30 am</td>
<td>PRE-MTG SYMP 5</td>
<td>PRE-MTG SYMP 6</td>
<td>PRE-MTG SYMP 7</td>
<td>MASTERS ACADEMY 10:30 am - 1:30 pm</td>
<td>PRE-MTG SYMP 16</td>
<td>LungTx BMO</td>
<td>PRE-MTG SYMP 21</td>
<td>TRegs</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>MASTERS ACADEMY 12:30 pm</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>SUNRISE 1</td>
<td>SUNRISE 2</td>
<td>SUNRISE 3</td>
<td>SUNRISE 4</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>PRE-MTG SYMP 15</td>
<td>PRE-MTG SYMP 16</td>
<td>PRE-MTG SYMP 17</td>
<td>PRE-MTG SYMP 18</td>
<td>PRE-MTG SYMP 19</td>
<td>PRE-MTG SYMP 20</td>
<td>PRE-MTG SYMP 21</td>
<td>PRE-MTG SYMP 22</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Thromic Organ Lmts</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
<td>MASTERS ACADEMY</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Exhibit Hall Open</td>
<td>Exhibit Hall Open</td>
<td>Exhibit Hall Open</td>
<td>Exhibit Hall Open</td>
<td>Exhibit Hall Open</td>
<td>Exhibit Hall Open</td>
<td>Exhibit Hall Open</td>
<td>Exhibit Hall Open</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>PRE-MTG SYMP 23</td>
<td>PRE-MTG SYMP 24</td>
<td>PRE-MTG SYMP 25</td>
<td>PRE-MTG SYMP 26</td>
<td>PRE-MTG SYMP 27</td>
<td>PRE-MTG SYMP 28</td>
<td>PRE-MTG SYMP 29</td>
<td>PRE-MTG SYMP 30</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>PRE-MTG SYMP 31</td>
<td>PRE-MTG SYMP 32</td>
<td>PRE-MTG SYMP 33</td>
<td>PRE-MTG SYMP 34</td>
<td>PRE-MTG SYMP 35</td>
<td>PRE-MTG SYMP 36</td>
<td>PRE-MTG SYMP 37</td>
<td>PRE-MTG SYMP 38</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>PRE-MTG SYMP 39</td>
<td>PRE-MTG SYMP 40</td>
<td>PRE-MTG SYMP 41</td>
<td>PRE-MTG SYMP 42</td>
<td>PRE-MTG SYMP 43</td>
<td>PRE-MTG SYMP 44</td>
<td>PRE-MTG SYMP 45</td>
<td>PRE-MTG SYMP 46</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>PRE-MTG SYMP 47</td>
<td>PRE-MTG SYMP 48</td>
<td>PRE-MTG SYMP 49</td>
<td>PRE-MTG SYMP 50</td>
<td>PRE-MTG SYMP 51</td>
<td>PRE-MTG SYMP 52</td>
<td>PRE-MTG SYMP 53</td>
<td>PRE-MTG SYMP 54</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>PRE-MTG SYMP 55</td>
<td>PRE-MTG SYMP 56</td>
<td>PRE-MTG SYMP 57</td>
<td>PRE-MTG SYMP 58</td>
<td>PRE-MTG SYMP 59</td>
<td>PRE-MTG SYMP 60</td>
<td>PRE-MTG SYMP 61</td>
<td>PRE-MTG SYMP 62</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
<td>Box Lunches</td>
</tr>
</tbody>
</table>
**AT A GLANCE**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td>SUNRISE 1</td>
</tr>
<tr>
<td>7:30 am</td>
<td>Registration</td>
</tr>
<tr>
<td>8:00 am</td>
<td>PLenary Session</td>
</tr>
<tr>
<td>8:30 am</td>
<td>Crystal Ball</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Concurrent 1</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Annual Biz Mtg</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Concurrent 18</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Lung Future Therapies</td>
</tr>
<tr>
<td>11:30 am</td>
<td>Sharing Hearts</td>
</tr>
<tr>
<td>12:00 pm</td>
<td>Box Lunches</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>MINI ORALS 5</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>HTx Debates</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Break</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Break</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>Break</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>5:00 pm</td>
<td>Break</td>
</tr>
<tr>
<td>5:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>6:00 pm</td>
<td>Break</td>
</tr>
<tr>
<td>6:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>7:00 pm</td>
<td>GALA Reception</td>
</tr>
<tr>
<td>7:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>8:00 pm</td>
<td>Break</td>
</tr>
<tr>
<td>8:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>9:00 pm</td>
<td>Break</td>
</tr>
<tr>
<td>9:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>10:00 pm</td>
<td>Break</td>
</tr>
<tr>
<td>10:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>11:00 pm</td>
<td>Break</td>
</tr>
</tbody>
</table>

**Events:**
- **SUNRISE:** Registration, Box Lunches, Exhibit Hall
- **PLenary Session:** Crystal Ball, Exhibit Hall
- **Concurrent:** Various sessions throughout the day, including breaks and meals.

**Locations:**
- Sapphire Center
- Sapphire Pavilion
- Exhibit Hall
- Box Lunches

**Registration:**
- 7:00 am - 5:30 pm

**Additional Information:**
- **Breaks:** Occur multiple times throughout the day for meals and rest.
- **Exhibit Hall:** Open throughout the day for various activities.
- **Box Lunches:** Available during specified times.

**Catering:**
- Box Lunches are provided at specific times.

**Final Details:**
- The schedule includes various sessions, breaks, and meals, ensuring a full day of activities.

**Contact:**
- For more information, please contact the organizers.

**Location:**
- Sapphire Center
- Sapphire Pavilion
- Exhibit Hall
Registration
Registration for the meeting must be made online via the ISHLT web site or via the Official ISHLT Registration Form. Online registration is strongly encouraged. A $100 discount off the registration fee is offered to those who register on or before March 2, 2011. Individuals who have not registered by March 18, 2011 must register on-site at the meeting. Confirmation letters will be emailed to all individuals who register by March 18, 2011.

Meeting Location
Unless otherwise noted, all meetings and activities will take place at the brand new Hilton San Diego Bayfront Hotel, One Park Blvd, San Diego, CA 92101. Sitting on one of the most spectacular locations along the Southern California coast, the Hilton San Diego Bayfront is a reflection of all the things that make San Diego shine. Built on the former site of a historic shipyard, the Hilton San Diego Bayfront echoes San Diego’s unique maritime heritage. At every window you can see the vast diversity of San Diego Bay, from sleek sailing ships beneath the majestic Coronado Bridge to naval and commercial vessels. You might even catch the U.S. Navy Seals training in the waters of San Diego Bay or see large cargo ships delivering bananas and pineapples from Costa Rica.

Hotel Reservations
ISHLT has arranged for a large block of sleeping rooms at the Hilton San Diego Bayfront Hotel at One Park Avenue, San Diego, CA 92101. To obtain rooms within this block and at ISHLT’s rates, you must make your reservation using the Official ISHLT Housing Form or online (see link on ISHLT Housing Form). A Housing Form is enclosed with this program. Additional copies may be obtained from the Society Web Site (www.ishlt.org), the Society Headquarters at 972-490-9495 or you may photocopy the enclosed forms. Hotel reservations must be made no later than March 12, 2011 in order to secure the ISHLT rate. Rooms are limited so please book early.
Accreditation
The Annual Meeting has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this educational activity for a maximum of 36 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Category 1 Continuing Education Points for Transplant Certification (CEPTCs) have been applied for through the American Board for Transplant Certification (ABTC).

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Educational Objectives
The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

Educational Goals
The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies and medical advances related to heart and lung transplantation and end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate and examination regarding the efficacy and applicability of these current practices, emerging technologies and medical advances.

Target Audience
The audience for this program includes physicians, surgeons, scientists, nurses and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields or specialties which cause them to become involved in the treatment of transplant recipients or patients with end-stage heart or lung disease.
On Wednesday, April 13, 21 Pre-Meeting Symposia will be presented throughout the day in six concurrent session rooms. Sessions will begin at 8:00 am and each session will be two hours in length. The content of the Pre-Meeting Symposia was designed specifically in response to recommendations from our membership.
The ISHLT Annual Meeting will officially run for four full days, from 8:00 am Wednesday, April 13 through 4:40 pm Saturday, April 16, allowing convenient early departures from San Diego to US and international destinations on Sunday April 17. Plenary Sessions will highlight material of general interest to ISHLT’s diverse membership, including the Pioneer Lecture by Elizabeth Hammond, debates between prominent members on “hot” topics (choices after age 70; obesity as a contraindication to transplantation) and top-ranked abstracts. Thirteen Mid-Day Symposia will offer affordable box lunches (be sure to pre-order your lunch!) and will present additional content requested by our membership’s various constituencies, including hot translational research topics and clinical management controversies. Six oral abstract presentation sessions will run simultaneously during each Concurrent Abstract Session and will feature oral abstracts submitted by the membership and selected by blinded peer-review; overall, 52 individual oral and mini-oral abstract sessions are distributed across the four days of the meeting. Fourteen Sunrise Symposia (7 – 8 am, Thursday through Saturday) will cater to the needs and interests of 14 smaller subspecialty groups.

Tuesday April 12th is reserved for pre-meeting conferences, committee meetings and the ISHLT Board meeting. Registration and the Speaker Ready Room will open at 5:00 pm on Tuesday.

Some highlights of each of these program elements are described on the following pages in greater detail.

Scientific Council Meetings will be held on Wednesday during the lunch break and following the scientific sessions and on Thursday following the scientific sessions. Councils are being asked to play an increasingly important role in developing content for the annual meetings, as well as guidelines, consensus documents and monographs. Please make time to attend and participate in the Council Meetings.

We have scheduled them to involve minimal overlap with each other in order to facilitate Council meeting attendance and participation. The Junior Faculty and Trainee Council will meet on Friday after the scientific sessions, to avoid overlap with any other Councils. Also, the newly formed Basic Science and Translational Research Council will meet on Wednesday after the scientific session to encourage broad multidisciplinary involvement and participation. Council reports to the ISHLT Board and membership will take place on Saturday during the lunch break. All members who are interested in finding out more about what the various councils are engaged in are encouraged to attend.
Pre-Meeting Symposia
Working primarily from excellent suggestions made by members of the Councils, the program committee worked hard to develop a full day of content of interest to each of our major constituencies (heart and lung transplantation, MCS, heart failure, pulmonary hypertension, pediatrics, allied health and social science, infectious disease, basic science, and pathology).

Featured topics will include: antibody-mediated and chronic rejection of heart and lung allografts; microvascular biology; pulmonary hypertension management options; donor organ optimization, allocation and alternatives; infectious disease (CMV: the gathering storm); and multiple perspectives on mechanical heart and lung support (prevention and treatment of RV failure, peri-operative application in lung transplant recipients, and evolving options for infants and children).

Plenary Sessions
Plenary Sessions will feature presentations by leaders in our Society as well as invited speakers whose contributions in related fields offer fresh perspectives that we may be able to apply to the care of our patients. On Friday, “Gazing Into the Crystal Ball – Emerging Therapy in Thoracic Transplantation” will highlight clinical immune modulation (David Wilkes), alternatives for survivors of CHD, (Felix Berger), cell-based alternatives to MCS (Eduardo Marban), repairing and re-engineering lungs for transplant (Shaf Keshavjee) and expected progress with lung assist devices (Joseph Zwischenberger). Saturday morning will feature Walter Dembitsky, talking about “MCS Evolution And Counter-Evolution: Can We Fool Mother Nature?” and Lynne Stevenson will moderate an expert panel (Roland Hetzer, Nicholas Smedira, Heather Ross) discussing “Choices After Age 70: MCSD, Heart Transplant or Palliative Care.” On Saturday afternoon, the Closing Plenary Session will feature a Keynote Lecture, “Proteomics/ Novel Diagnostics In Transplantation” by Daniel Salomon, a lecture by Frank Delmonico entitled “ISHLT, TTS and WHO: An Emerging International Public Policy Initiative for Promoting Organ Donation,” a “What’s Hot/What’s Cool” summary of the meeting covering the field of heart failure and transplant (Mandeep Mehra), lung failure and transplant (Allan Glanville), MCS (Francis Pagani) and Basic Science and Immunobiology (Stephen Ensminger), followed by a spirited “Supersize Me” debate between Marshall Hertz and John Wallwork regarding the proposition: “Obesity Is NOT a Contraindication To Thoracic Replacement Therapy.”
**Mechanical Circulatory Support**

The 31st Annual Meeting and Scientific Sessions of ISHLT will have a record number of presentations addressing the challenges of patient selection for mechanical circulatory support (MCS), clinical management of the MCS patient, and recommendations to reduce adverse events. A Mid-Day Symposium on Pediatric VADs will include: special anatomic and physiologic considerations complicating MCS implant in CHD (Eric Devaney); current device options for the single ventricle (Michael Hubler); an update on the North American experience with pediatric VADs (Holger Buchholz); and an update on the NIH PumpKIN trial (Bartley Griffith). Among the other offerings are popular staples from prior years (VADs Gone Bad; RV support during and after LVAD implantation). MCS case presentation sessions have been particularly popular at prior meetings and the San Diego program will offer added opportunities for members to participate actively in these sessions.

**Pulmonary Hypertension**

This year, the PH members of the Program Committee have put together a diverse and exciting series of pre-meeting and mid-day symposia to discuss emerging options for the management of advanced PH. The Program Committee and the PH Council will take advantage of the meeting’s location to highlight important contributions by local members of our society, complemented by presentations from some of the leading authorities in the world. An important theme throughout the meeting will be a focus on right ventricular (dys)function, its assessment through imaging and other modalities, its management in the context of heart and lung transplant and in conjunction with MCS and ECMO support. For example, don’t miss the Friday Sunrise Symposium on “Pulmonary Hypertension Complicating Left Ventricular Failure: Problems and Progress.” On the whole, the San Diego meeting offers a great opportunity to learn more about primary and secondary pulmonary hypertension and their management.
Infectious Disease
San Diego will feature cutting edge developments in the diagnosis and management of infectious diseases in thoracic transplant and MCSD patients. In addition to Pre-Meeting Symposium updates on CMV (“The Gathering Storm”), we will be entertained (“What’s Fester?”) and enlightened (“Microbe Hunters – Munitions, Germs and Steel”) by leaders in the field during other Mid-Day and Sunrise Symposium sessions throughout the meeting. Additional talks highly relevant to infectious disease specialists working with thoracic transplant and MCSD patients and specifically useful to guide difficult clinical treatment decisions, will be found throughout the Symposium and Concurrent Oral Abstract sessions.

Pediatric Transplantation
There are many sessions that are tailored to the particular interest to the pediatric heart and lung transplant community. Of particular note are a Wednesday Pre-Meeting Symposium in conjunction with IPTA to ask “Do We Have a Consensus?” with respect to donor and recipient selection criteria and post-transplant management approaches and a Thursday Mid-Day Symposium on pediatric VAD and ECMO technology.

Basic Science
The “Caves Award” competition session will continue to highlight original research by our young academic scientists, who present their “hottest” experimental and clinical research to a jury of senior scientists and interested members. Translational science will be particularly highlighted in Plenary and Mid-Day Symposium sessions. Most notably, Dan Salomon’s Saturday Keynote Plenary lecture will discuss proteomics and other evolving diagnostic tools that are likely to find their way to our patients’ bedsides during the next decade. Another session not to be missed is Thursday’s “Immunological Aspects of Engineered Heart Tissue and Cellular Replacement Therapies,” discussing how immunity influences progress related to engineered heart tissue (Thomas Eschenhagen), augmenting cardiomyocyte proliferation in the failing heart (Loren Field) and emerging stem cell-based therapies (Stefan Janssens).
Nursing, Health Science and Allied Health

Our 2011 Annual Meeting program has been constructed and designed based on extensive feedback and helpful program evaluations from our nursing science, social science and allied health colleagues. Thanks to the enthusiastic engagement of their Council, the nursing and social science content of this year’s meeting will be enriched by discussion of “new solutions to old problems,” of palliative care’s role in the management of difficult patient scenarios and of activities and strategies that are associated with improved quality of life.

Pathology

This year’s Annual Meeting will emphasize features of AMR in clinical heart and lung transplantation, including the latest guidance regarding detection and management of antidonor antibodies. Significant advances in the use of molecular tools to detect rejection, anticipate graft acceptance (tolerance) and diagnose rejection will be highlighted in Daniel Salomon’s Keynote Plenary talk and in multiple other areas of the program. In addition, the latest data will be presented in oral abstract sessions regarding cellular mechanisms of chronic heart and lung rejection (CAV, OBS), PTLD and other malignancies, pathobiology of AMR and the role of innate and adaptative immunity in the pathogenesis of early and late thoracic organ failure.
Junior Faculty & Trainees
Continuing last year’s successful new offerings for Junior Faculty and Trainees, in San Diego there will again be a “Mentor Lunch,” where junior faculty and trainees can be mentored on “Getting Your Next Job,” “Balancing Work and Family,” and other topics of special interest to these members (pre-registration is required and limited). In addition, “Clinical Case Dilemmas in Thoracic Transplantation” will return, where tough cases are presented by junior faculty to expert discussants. **Note that these cases must be submitted via the standard abstract submission process, the deadline for which is November 19.** All are welcome to observe and to join in the resulting lively discussions. Case presentation sessions have been particularly popular among junior faculty and trainees, and the San Diego program will offer added opportunities for junior members to participate actively in these sessions.

Pulmonary Transplantation
As one of the core disciplines at the foundation of our society, lung failure management and pulmonary replacement therapy will be prominent topics in multiple sessions. In addition to “Crystal Ball” Plenary session talks highlighting emerging new treatment approaches and technologies (repairing and re-engineering lungs for transplant by Shaf Keshavjee and expected progress with lung assist devices by Joseph Zwischenberger), multiple Mid-Day, Pre-Meeting and Sunrise Symposia will focus on new evidence and remaining controversies important to clinicians working with lung transplant patients. These presentations, and the eight concurrent oral abstract sessions devoted to lung failure and lung transplantation, as well as extensive additional offerings related to pulmonary hypertension, right heart failure and ECMO, should prove to be of particular interest to those engaged in these fields.

ISHLT 31st ANNUAL MEETING

SCIENTIFIC HIGHLIGHTS
Heart Failure and Transplant Medicine

As another of the core disciplines at the foundation of our society, heart failure management and cardiac replacement and repair therapies will be prominent topics in multiple sessions. In addition to Pre-Meeting Symposium sessions highlighting emerging new treatment approaches and technologies (donor organ selection and rejuvenation; diagnosis and treatment of cardiac AMR; CAV consensus and controversy), multiple Mid-Day and Sunrise Symposia will focus on new evidence and remaining controversies important to clinicians working with cardiac transplant and heart failure patients. Thursday’s “Immunological Aspects of Engineered Heart Tissue and Cellular Replacement Therapies in Heart Failure” will feature cutting-edge talks by Thomas Eschenhagen, Loren Field and Stefan Janssens, and will be moderated by Sonja Schrejer and Doris Taylor, whose own work will be highlighted on Friday. On Friday, international transplant practices will be compared in a Saturday Mid-Day Symposium on “Sharing Hearts Around the World: What Works and What Fails in National Systems.” A Saturday Mid-Day Symposium highlight will be three “great debates” in cardiac transplant immunosuppression, regarding universal use of “induction” therapy, routine steroid withdrawal by three months and uniform substitution of an mTOR inhibitor for a CNI within the first year. These presentations, and the eight concurrent oral abstract sessions devoted to heart failure and cardiac transplantation, should prove to be of particular interest to those engaged in these fields.

President’s Gala Reception

The President’s Gala Reception will be held Friday evening on the hotel premises for maximum convenience and attendance. The Gala will encompass the hotel ballroom as well as the lovely adjacent outdoor terrace, offering stunning views of the San Diego Bay and the sunset. As always, you can expect plenty of food, drink, music and friends.
Tuesday, April 12, 2011

8:00 am – 2:00 pm
ISHLT Board of Directors Meeting

Noon – 9:00 pm
Speaker Ready Room Open

2:00 pm – 4:00 pm
Thoracic Registry Steering Committee Meeting
Education Committee Meeting

2:00 pm – 9:00 pm
isht academy: Core Competencies In Lung Transplantation

4:30 pm – 6:30 pm
Registries and Databases Committee Meeting
Standards and Guidelines Committee Meeting
Communications Committee Meeting

5:00 pm – 8:00 pm
Registration Open
Wednesday, April 13, 2011

6:30 am – 6:30 pm
Speaker Ready Room Open

6:45 am – 7:45 am
Corporate Council Breakfast Meeting

7:00 am – 6:30 pm
Registration Open

7:30 am – 12:15 pm
ishlt academy: Core Competencies in Lung Transplantation

8:00 am – 10:00 am
Pre-Meeting Symposium 1: “Risky Business!”
Heart Failure, Transplant And Mechanical Circulatory Support

CHAIRS: Joseph G. Rogers, M D and Axel Rahmel, M D

8:00 am  Assessment Of Heart Failure Risk, Wayne C. Levy, M D, University of Washington Medical Center, Seattle, Washington
8:15 am  Assessment Of Transplant Risk In The Us, D. Bradley S. Dyke, M D, University of Michigan, Ann Arbor, Michigan
8:30 am  Assessment Of Transplant Risk In Europe, Bruno M. M eiser, M D, University of Munich/ Grosshadern, Munich, Germany
8:45 am  Assessment Of M CS Risk, Katherine Lietz, M D, PhD, Yale University School of Medicine, New Haven, Connecticut
9:00 am  Assessing The Risk Of What?, Keith D. Aaronson, M D, University of Michigan Medical Center, Ann Arbor, Michigan
9:15 am  Modeling Risk For Individual Patients, David C. Naftel, M D, University of Alabama at Birmingham, Alabama
9:30 am  Case Discussions
9:30 am  Chetan Patel, M D, Duke University Medical Center, Durham, North Carolina
9:38 am  Alexander Stepanenko, M D, German Heart Institute, Berlin, Germany
9:45 am  Panel Discussion

8:00 am – 10:00 am
Pre-Meeting Symposium 2: Preserving Microvascular Function In Lung Transplantation

CHAIRS: Marlene Rose, PhD and Scott M. Palmer, M D, M H

8:00 am  The Critical Role Of Airway Microvasculature In Lung Transplantation: An Overview Of Pre-Clinical And Clinical Studies, Mark R. Nicolls, M D, VA Palo Alto/Stanford University, Stanford, California
8:15 am  Lung Transplant Airway Hypoxia: A Diathesis To Fibrosis?, Gundeep S. Dhillon, M D, Stanford University Medical Center, Stanford, California
8:30 am  Bronchial Artery Revascularization: The Copenhagen And Cleveland Clinic Experience, Gosta Pettersson, M D, Cleveland Clinic Foundation, Cleveland, Ohio
8:45 am  Microvascular Rarefaction In BOS: Results Of The Papworth Hospital Autopsy Study, Martin J. Goddard, FRCS, M RCPa, Papworth Hospital NHS Trust, Cambridge, United Kingdom
9:00 am  The Microvasculature In Solid Organ Transplantation, Jan Hillebrands, M D, University of Groningen Medical School, Groningen, The Netherlands
9:20 am  Preserving Airway Microvasculature In Lung Transplantation: Looking To The Future, Martin R. Zamora, M D, University of Colorado Health Science Center, Aurora, Colorado
9:35 am  Discussion

8:00 am – 10:00 am
Pre-Meeting Symposium 3: Optimizing Lung Allocation. Square Pegs In Round Holes?

CHAIRS: Gregory I. Snell, FRCP, M BB and David J. Lederer, M D

8:00 am  North American Experience (Lung Allocation Score), Cynthia J. Gries, M D, M Sc, University of Pittsburgh Medical Center Montefiore, Pittsburgh, Pennsylvania
8:25 am  Lung Allocation Beyond The US, Paul A. Corris, M B FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
8:50 am  Pros And Cons Of Various Allocation Systems: An Independent Review, Lianne G. Singer, M D, FRCPC, Toronto General Hospital, Toronto, Canada
9:15 am  Should We Be Transplanting Patients From The Intensive Care Unit?, Selim M. Arcasoy, M D, Columbia University, New York, New York
9:40 am  Panel Discussion
8:00 am – 10:00 am
Pre-Meeting Symposium 4: Old Problems, New Solutions: Clinical Exemplars For Nursing, Health Sciences And Allied Health
CHAIRS: Sharon A. Beer, RN, M Sc and Sharon Augustine, CRNP

8:00 am Exemplar: Genomics And Coumadin, Bernice L. Coleman, PhD, RN, Cedars Sinai Medical Center, Los Angeles, California

8:25 am Exemplar: Translation Of Research To Practice, Judy A. Currey, PhD, Alfred Hospital/Deakin University, Melbourne, Australia

8:50 am Exemplar: Community Care Of The Transplant/ MCS Patient In A Nurse-Managed Clinic, Renee L. Lassinger, RN, MSN, ANP, M id-State Cardiology, Nashville, Tennessee

9:15 am Exemplar: New Adherence With Interventions For Organ Failure, Sabina M. De Geest, RN, PhD, University of Basel, Switzerland

9:40 am Audience Discussion: What Challenging Problems Have You Resolved Creatively?

10:00 am – 10:30 am
COFFEE BREAK

10:30 am – 12:30 pm
Pre-Meeting Symposium 5: Challenges In Lung Transplantation For Pulmonary Arterial Hypertension
CHAIRS: Reda E. Girgis, M B, BCh and Fernando Torres, M D, PA

10:30 am Impact Of LAS On Waiting List Mortality For PAH: What Has Changed And How Should It Be Refined?, Reda Girgis, M B, BCh, Johns Hopkins University, Baltimore, M aryland

10:50 am Management Of The Critically Ill PAH Patient On The Waiting List, M arc De Perrot, M D, Toronto General Hospital, Toronto, Canada

11:10 am Strategies To Reduce Primary Graft Dysfunction And Improve Short-Term Survival After Lung Transplantation For PAH, Jason D. Christie, M D, M S, University of Pennsylvania, Philadelphia, Pennsylvania

11:30 am Lung Transplantation And Right Ventricular Failure: When Is Heart-Lung Transplant Or Planned Post-Operative ECMO Support Required?, Walter Klepetko, M D, Vienna Medical University, Vienna, Austria

11:50 am Thoracic Transplantation For Adult Congenital Heart Disease: Timing Of Transplantation, Organ Utilization And Transplant Outcomes In This Growing Population, John Conte, M D, Johns Hopkins Hospital, Baltimore, M aryland

12:10 pm Panel Discussion

10:30 am – 12:30 pm
Pre-Meeting Symposium 6: AM R 1 – Role of Antibody Detection in the Diagnosis of AM R
CHAIRS: Desley Neil, BM edSc, M B and Adriana Zeevi, PhD

10:30 am Introduction, Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom

10:40 am Role Of Antibodies Assessment, Risk-Stratification And Interpretation Of HLA Antibodies In Heart And Lung Transplantation, Nancy L. Reinsmoen, PhD D Abhi, Cedars-Sinai Health Systems, Los Angeles, California

11:00 am Non-HLA Antibodies, Natural Antibodies And Other Issues In Assessing Risk For Heart Transplant Recipients, Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom

11:20 am Assessment Of HLA Class I And Class II Antibodies In Lung Transplantation And Pediatrics, Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

11:40 am Role Of Complement-Fixing And Non-Complement-Fixing Antibodies, William M. Baldwin, III, M D, Cleveland Clinic Foundation, Cleveland, Ohio

12:00 pm Emerging Markers Of Antibody M ediated Rejection, Michael C. Fishbein, M D, UCLA School of Medicine, Los Angeles, California

12:20 pm Panel Discussion

10:30 am – 12:30 pm
Pre-Meeting Symposium 7: Coronary Artery Vasculopathy: From Consensus To Controversy
CHAIRS: J on Kobashigawa, M D and Maria Crespo-Leiro, M D

10:30 am ISHLT Vasculopathy Nomenclature Consensus Statement, Maria G. Crespo-Leiro, MD, Hospital Universitario a Coruña, La Coruña, Spain

10:50 am Transplant Vasculopathy: An Overview, Hannah A. Valentine, M D, Stanford University School of Medicine, Stanford, California

11:15 am Role Of Endothelial Progenitor Cells, Sudhir S. Kushwaha, M D, Mayo Clinic, Rochester, M innesota

11:40 am The Endothelial Cell As A Target For Therapy, Monica M. Colvin-Adams, M D, University of M innesota, M inneapolis, M innesota
**11:30 am** Non-Invasive Risk Assessment And Diagnosis, Patricia P. Chang, M.D, University of North Carolina, Chapel Hill, North Carolina

**11:45 am** Strategies To Minimize The Development Of Coronary Vasculopathy, James C. Fang, M.D, University Hospital Case Medical Center, Cleveland, Ohio

**12:00 pm** Strategies To Treat Established Vasculopathy, Andreas O. Zuckermann, M.D, University of Vienna, Vienna, Austria

**12:15 pm** Discussion

---

**10:30 am – 12:30 pm**

**Pre-Meeting Symposium 8:** Extracorporeal Support In Lung Transplantation

**CHAIRS:** Duane Davis, M.D and Joseph B. Zwischenberger, M.D

**Part I:** How To Implant My Airbags? To Pump Or Not To Pump

**10:30 am** Why I Do All Cases Off Pump, Bryan F. Meyers, M.D, Washington University School of Medicine, St. Louis, Missouri

**10:45 am** Why I Do All Cases On Pump, Alberto Pochettino, M.D, University of Pennsylvania Health System, Philadelphia, Pennsylvania

**10:55 am** Discussion

**Part II:** Cardiopulmonary Bypass Strategies For Double Lung Transplant

**11:05 am** UCLA Experience, Abbas Ardehali, M.D, University of California Los Angeles, California

**11:15 am** Newcastle Experience, Stephen C. Clark, M.D, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**11:25 am** Vienna Experience, Clemens Aigner, M.D, Medical University of Vienna, Vienna, Austria

**11:35 am** Discussion

**Part III:** Applications Of ECMO For Lung Transplant

**11:45 am** Novalung As A Bridge, Martin Strueber, M.D, Hannover Medical School, Hannover, Germany

**11:55 am** Veno-Venous/Veno-Arterial ECMO As A Bridge, David P. Mason, M.D, Cleveland Clinic Foundation, Cleveland, Ohio

**12:05 pm** Veno-Venous/Veno-Arterial ECMO For PGD, Yoshiya Toyoda, M.D, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

**12:15 pm** Discussion
10:30 am – 12:30
Pre-Meeting Symposium 9:
CMV – The Gathering Storm
CHAIRS: Frauke Mattner, MD and Vincent G. Valentine, MD

10:30 am Preventing CMV – Our Finest Hour, Scott M. Palmer, MD, Duke University Medical Center, Durham, North Carolina

10:54 am CMV Immunoglobulin – The Grand Alliance?, Javier Carbone, MD, PhD, Gregorio Maranan Hospital, Madrid, Spain

11:18 am Treating Ganciclovir-Resistant CMV – Closing The Ring, Sangeeta M. Bhorade, MD, University of Chicago, Chicago, Illinois

11:42 am Pediatric Issues In CMV Management – The Hinge Of Fate, Lara Danziger-Isakov, MD, MPH, Cleveland Clinic Foundation, Cleveland, Ohio

12:06 pm Diagnostics Of CMV-Triumph And Tragedy, Glen P. Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia

12:45 pm – 1:45 pm
Box Lunch Pick-up
Heart Failure and Transplant Medicine Council Meeting
Pathology Council Meeting
Pediatric Transplant Council Meeting
Pulmonary Transplant Council Meeting

2:00 pm – 4:00 pm
Pre-Meeting Symposium 10: When Does “Less Sick” = “Sick Enough” for MCS?
CHAIRS: Jeffrey J. Teuteberg, MD and George M. Wiesenthaler, MD

2:00 pm How Many Walking Wounded Are There?, Randall C. Starling, MD, M PH, Cleveland Clinic Foundation, Cleveland, Ohio

2:15 pm Does Exercise Testing Evaluate Disease Severity In The Beta Blocker Era?, Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, Maryland

2:30 pm Quality Of Life As Potential Indication For VAD, Eldrin F. Lewis, MD, M PH, Brigham & Women’s Hospital, Boston, Massachusetts

2:45 pm Should Inotropic Therapy Come Before VAD?, Debra L. Isaac, MD, Foothills Hospital, University of Calgary, Calgary, Alberta, Canada

3:00 pm What Are The Tipping Points?, Lee R. Goldberg, MD, M PH, University of Pennsylvania, Philadelphia, Pennsylvania

3:15 pm Is There A Different Threshold For VAD When Transplant Is Not An Option?, Michael A. Acker, MD, University of Pennsylvania, Philadelphia, Pennsylvania

3:30 pm Differences In National Regulatory Perspectives, Ileana L. Pina, MD, VA Medical Center, Case Western, Cleveland, Ohio

3:45 pm Panel Discussion

2:00 pm – 4:00 pm
Pre-Meeting Symposium 11: AMR II: AMR In The Lung: Controversies In Clinical Treatment And Diagnosis
CHAIRS: Deborah J. Levine, MD and Allan R. Glanville, MD, FRACP

2:00 pm Introduction, Allan R. Glanville, MD, FRACP, St. Vincent’s Hospital, Sydney, Australia

2:10 pm Antibody Mediated Rejection In Solid Organ Transplantation, Thalachallour Mohanakumar, PhD, Washington University School of Medicine, St. Louis, Missouri

2:30 pm Pulmonary AMR: Acute And Chronic Presentation And Outcomes, Todd L. Astor, MD, Ohio State University, Columbus, Ohio

2:50 pm A Multi-Disciplinary Approach To Pulmonary AMR: Working Towards A Universal Paradigm: Clinically And Pathologically, Deborah J. Levine, MD, University of Texas Health Science Center, San Antonio, Texas

3:10 pm Improved Clinical Outcomes In The Pre-Sensitized Lung Transplant Recipient, Duane Davis, MD, Duke University Medical Center, Durham, North Carolina

3:30 pm Therapeutic Interventions For Pulmonary AMR: A Moving Target

3:30 pm A. Interventions (Plasmapheresis/IVIG), Lianne G. Singer, MD, FRCP, Toronto General Hospital, Toronto, Canada

3:40 pm B. Pharmacologic Therapies (Velcade), Sangeeta M. Bhorade, MD, University of Chicago, Chicago, Illinois

3:50 pm Panel Discussion

2:00 pm – 4:00 pm
Pre-Meeting Symposium 12: Clinical Challenges In Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
CHAIRS: Marion Delcroix, MD and Stuart W. Jamieson, MB, FRCS
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td>CTEPH Pathogenesis, Irene Lang, M.D., University of Vienna, Austria</td>
</tr>
<tr>
<td>2:20 pm</td>
<td>Diagnosis And Imaging In Evaluating A Patient With CTEPH: What Every Physician Should Know, Nick H. Kim, M.D., University of California San Diego, San Diego, California</td>
</tr>
<tr>
<td>2:40 pm</td>
<td>The European CTEPH Registry, Marion Delcroix, M.D., University Hospital Leuven, Belgium</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Should Pulmonary Vasodilators Be Used As A “Bridge” To Pulmonary Thromboendarterectomy? What Is The Role Of Medical Therapy For CTEPH?, Wiliam R. Auger, M.D., University of California San Diego, San Diego, California</td>
</tr>
<tr>
<td>3:20 pm</td>
<td>Pulmonary Thromboendarterectomy From A Surgeon’s Perspective, Michael M. Madani, M.D., University of California San Diego, San Diego, California</td>
</tr>
<tr>
<td>3:40 pm</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Pre-Meeting Symposium 13: What’s Festering?</td>
</tr>
<tr>
<td></td>
<td>CHAIRS: Margaret M. Hannan, M.D. and Valentina Stosor, M.D.</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Of Mycelia In Transplantation, Sam S. Weigt, M.D., UCLA, Los Angeles, California</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Of Bacteria And Transplantation, Margaret M. Hannan, M.D., Mater Hospital, Dublin, Ireland</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Sense And Sensibilities Of Fungal Diagnostics, Shahid Husain, M.D., M.S., Toronto General Hospital, Toronto, Canada</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Strengths And Frailties Of PCR For CM V-EBV, Jutta Preiksaitis, Alberta Provincial Lab for Public Health, Edmonton, Canada</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Pre-Meeting Symposium 14: Preventable Death: Kids On The Wait List</td>
</tr>
<tr>
<td></td>
<td>CHAIRS: Elfriede Pahl Schuette, M.D. and Carol K. Conrad, M.D.</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Why Are Children Disadvantaged On The Thoracic Transplant Waiting List?, Stuart C. Sweet, M.D., St. Louis Children’s Hospital, St. Louis, Missouri</td>
</tr>
<tr>
<td>2:20 pm</td>
<td>Surgical Techniques To Address Donor-Recipient Size Mismatch, Takahiro Oto, M.D., Okayama University Hospital, Okayama, Japan</td>
</tr>
<tr>
<td>2:40 pm</td>
<td>How The Berlin Heart Has Impacted Decision Making In Critically Ill Heart Transplant Candidates, Ivan M. Rebejka, M.D., University of Alberta Hospital, Edmonton, Canada</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Can We Save The Critically Ill Child: Transplanting From ICU, George B. Mallory, J.R., M.D., Texas Children’s Hospital, Houston, Texas</td>
</tr>
<tr>
<td>3:20 pm</td>
<td>DCD Heart Transplant: Is It Time?, Asif Hasan, M.D., Freeman Hospital, Newcastle Upon Tyne, United Kingdom</td>
</tr>
<tr>
<td>3:40 pm</td>
<td>Increasing Organ Donation Rates: The Impact Of DCD, Gregory L. Snell, FRACP, M.B.B., Alfred Hospital, Melbourne, Australia</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>2:00 pm – 4:00 pm Pre-Meeting Symposium 15: Quality Of Life In The Interventions For End-Stage Thoracic Organ Disease</td>
</tr>
<tr>
<td></td>
<td>CHAIRS: Nancy P. Blumenthal, CRNP and Fabienne Dobbels, M.Sc., PhD</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>M.C.S.D., Kathleen L. Grady, Ph.D., APN, FAAN, Northwestern Memorial Hospital, Chicago, Illinois</td>
</tr>
<tr>
<td>2:20 pm</td>
<td>Heart Transplantation, Heike Spaderna, Ph.D., Johannes Gutenberg University, Mainz, Germany</td>
</tr>
<tr>
<td>2:40 pm</td>
<td>Lung Transplantation, Susan M. Chernenko, R.N., M.N., NP, Toronto General Hospital, Toronto, Canada</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Pediatric Transplantation, John Wray, Ph.D., Royal Brompton and NHS Trust, Great Ormond Street Hospital, London, United Kingdom</td>
</tr>
<tr>
<td>3:20 pm</td>
<td>Pulmonary Hypertension, Jessica Lazar, PA-C, Allegheny General Hospital, Pittsburgh, Pennsylvania</td>
</tr>
<tr>
<td>3:40 pm</td>
<td>Audience Discussion – What Challenging Problems Have You Resolved Creatively?</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>4:00 pm – 4:30 pm COFFEE BREAK</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>4:30 pm – 6:30 pm Pre-Meeting Symposium 16: Management Of The Failing Right Ventricle At The Time Of MCS Implant</td>
</tr>
<tr>
<td></td>
<td>CHAIRS: Thomas Krabatsch, M.D. and Robert L. Kormos, M.D.</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Assessing Right Ventricular Function, Guy A. MaccGowan, M.D., Freeman Hospital, Newcastle Upon Tyne, United Kingdom</td>
</tr>
<tr>
<td>4:50 pm</td>
<td>Biventricular Failure: Lessons Learned From The INTERMACS Experience, Robert L. Kormos, M.D., University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania</td>
</tr>
<tr>
<td>5:10 pm</td>
<td>Current TAH/Paracorporeal BiVAD Support Options, Pascal Leprince, M.D., PhD, Hospital Pitie-Salpetriere, Paris, France</td>
</tr>
</tbody>
</table>
**5:30 pm**  Management Of The Tricuspid Valve In The Face Of Biventricular Failure – Getting By Without An RVAD, Carmelo Milano, MD, Duke University Medical Center, Durham, North Carolina

**5:50 pm**  When Is Temporary RVAD Support Enough?, Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Canada

**6:10 pm**  New Continuous Flow TAH/BiVAD Support Strategies, Roland Hetzer, MD, PhD, German Heart Institute, Berlin, Germany

**4:30 pm – 6:30 pm**  Pre-Meeting Symposium 17: AMR3 – The Role Of Pathology In Diagnosis Of AMR In The Heart

**CHAIRS:** Margaret M. Burke, FRCPath and Maria G. Crespo-Leiro, MD

- **4:30 pm**  Introduction, Annalisa Angelini, MD, University of Padua, Padova, Italy
- **4:40 pm**  Current Status Of Histopathological Diagnosis Of AMR, Gerald J. Berry, MD, Stanford University, Stanford, California
- **5:00 pm**  Correlation Between IF And ICH Techniques: Are They Equivalent?, E. René Rodríguez, MD, Cleveland Clinic Foundation, Cleveland, Ohio
- **5:20 pm**  Clinical Signs of AMR, When to Treat, Nicholas R. Banner, FRCP, Harefield Hospital, Harefield, United Kingdom
- **5:40 pm**  Therapeutic Intervention for AMR, Gareth Parry, M B, FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
- **6:00 pm**  New Therapies: Complement Blockade, Carl Atkinson, PhD, Medical University of South Carolina, Charleston, South Carolina
- **6:20 pm**  Panel Discussion

**4:30 pm – 6:30 pm**  Pre-Meeting Symposium 18: Donor Organ Optimization

**CHAIRS:** Bruce R. Rosengard, M D, FRCS and Andres Varela, M D

- **4:30 pm**  Clinical Experience With Ex Vivo Lung Perfusion, Shaf Keshavjee, MD, FRCS, Toronto General Hospital, Toronto, Canada
- **5:00 pm**  Warm Blood Perfusion For Heart Preservation, Christoph Knosalla, M D, PhD, German Heart Institute, Berlin, Germany
- **5:30 pm**  Lungs From DCD Donors – A Better Source Than Brain-Dead Donors?, Karen Redmond, FRCS (C-R), Harefield Hospital, Harefield, United Kingdom

**4:30 pm – 6:30 pm**  Pre-Meeting Symposium 19: Obliterative Bronchiolitis: Translation Of Cells To Patients

**CHAIRS:** Annette Boehler, M D and Christopher H. Wigfield, FRCS

- **4:35 pm**  What Is The Role Of Airway Epithelium In The Development Of OB?, Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
- **4:55 pm**  Where Does Airway Fibrosis In OB Come From?, Daniel C. Chambers, M BBS, M D, The Prince Charles Hospital, Brisbane, Australia
- **5:20 pm**  Does Airway Smooth Muscle Contribute To The Development Of OB?, Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium
- **5:45 pm**  Does The Endothelial Cell Contribute To OB?, John A. Belperio, MD, PhD, University School of Medicine at UCLA, Los Angeles, California
- **6:10 pm**  Putting It All Together: Implications For Future Therapies, Robert M. Aris, M D, University of North Carolina, Chapel Hill, North Carolina

**4:30 pm – 6:30 pm**  Pre-Meeting Symposium 20: Pediatric Cardiothoracic Transplant: Do We Have Consensus? (Presented in collaboration with the International Pediatric Transplant Association)

**CHAIRS:** Richard Kirk, M A, FRCP, FRCPCH, Samuel B. Goldfarb, M D and Anne I. Dipchand, M D

- **4:30 pm**  Heart: Who Should We List?, Robert G. Weintraub, M B, BS, FRACP, FACC Royal Children’s Hospital, Melbourne, Australia
- **4:50 pm**  Lung: Who Should We List?, Albert Faro, M D, Washington University School of Medicine, St. Louis, Missouri
- **5:10 pm**  Heart: Who Is A Good Donor?, Kirk R. Kanter, M D, Emory University, Atlanta, Georgia
- **5:30 pm**  Lung: What Is A Good Donor?, Melinda P. Solomon, M D, FRCP, Hospital for Sick Children, Toronto, Canada
- **5:50 pm**  Heart: Consensus In Post-Transplant Management?, Michael Burch, M D, Great Ormond Street Hospital, London, United Kingdom

**6:00 pm**  DCD Donor Resuscitation With Extracorporeal Support, Michael H. Hines, M D, Wake Forest University, Winston-Salem, North Carolina
Thursday, April 14, 2011

6:30 am – 6:30 pm
Speaker Ready Room Open

7:00 am – 5:30 pm
Registration Desk Open

7:00 am – 8:00 am
Sunrise Symposium 1: The Role of IL17 In Lung Transplantation
CHAIRS: Thalachallour M ohanakumar, PhD and Gregory I. Snell, FRCP, MBB

7:00 am IL-17 In Organ Transplantation: Where Does It Come From?, Behdad (Ben) Afzali, MD, Guy's Hospital, London, United Kingdom

7:20 am Innate Immunity In The Transplanted Lung: The Role Of IL-17, Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

7:40 am IL-17 In Acute And Chronic Lung Rejection: Implications For Treatment, Geert M. Verleden MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

7:00 am – 8:00 am
Sunrise Symposium 2: VADS Gone Bad
CHAIRS: Soon Park, M D and Matthias Loebe, M D, PhD

7:00 am Case Of Inlet Canular Obstruction, Matthias Loebe, M D, PhD, Baylor College of Medicine, Houston, Texas

7:15 am The Recurring Infection, Margarita T. Camacho, M D, Newark Beth Israel Medical Center, Newark, New Jersey
7:30 am  The Leaking Valve, Nader Moazami, MD, Minneapolis Heart Institute, Minneapolis, Minnesota

7:45 am  Where Oh Where Am I Bleeding From?, Ulrich P. Jorde, MD, Columbia University, New York, New York

7:00 am – 8:00 am  Sunrise Symposium 3: Collagen Vascular Disease – The Skinny On A Hard Disease
CHAIRS: James C. Lee, MD and Martin Carby, MBBS

7:00 am  Scleroderma As A Cause Of Advanced Lung Disease, Steven D. Nathan, MD, Fairfax Inova Hospital, Falls Church, Virginia

7:15 am  Should We Be Transplanting Patients With Collagen Vascular Disease?, Lieven J. Dupont, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

7:30 am  Surgical Approaches To Scleroderma GI Disease And Their Efficacy, Duane Davis, MD, Duke University Medical Center, Durham, North Carolina

7:45 am  Panel Discussion

7:00 am – 8:00 am  Sunrise Symposium 4: Microbe Hunters - Munitions, Germs and Steel: A Case-Based Discussion
CHAIRS: Kate Gould, FRCPath and Fernanda P. Silveira, MD
7:00 am  Fighting Fungi, Shahid Husain, MD, M S,  
Toronto General Hospital, Toronto, Canada

7:12 am  Nucleic Warfare, Allan R. Glanville, MD,  
FRACP, St. Vincent's Hospital, Sydney, Australia

7:24 am  Infected Ti22 – Fall Of The Machine, Martha  
L. M. ooney, M D, Sentara Norfolk Transplant Center/  
EVM S, Norfolk, Virginia

7:36 am  Battling Bacteria, Juliet E. Foweraker, M D,  
PhD, Papworth Hospital NHS Foundation Trust, Cam-  
bridge, United Kingdom

7:48 am  Panel Discussion

8:00 am – 10:00 am  
Opening Plenary Session

CHAIRS:  John Dark, MB, FRCS and  
Richard N. Pierson, III, M D

8:00 am  Welcome, John Dark, MB, FRCS, ISHLT Presi-  
dent, Freeman Hospital, Newcastle Upon Tyne, United  
Kingdom

8:05 am  Program Chair Report, Richard N. Pierson, III,  
M D, 2011 Scientific Program Chair, University of Mary-  
land, Baltimore, Maryland

8:15 am  Thoracic Registry Report, Marshall Hertz,  
M D, University of Minnesota, Minneapolis, Minnesota

8:35 am  INTERMACS Report, James K. Kirklin, M D,  
University of Alabama at Birmingham, Alabama

8:45 am  Presidential Address, John Dark, MB FRCS,  
Freeman Hospital, Newcastle Upon Tyne, United King-  
dom

8:55 am  Pioneer Lecture, Elizabeth Hammond, M D,  
University of Utah School of Medicine, Salt Lake City,  
Utah

9:15 am  Featured and Late-Breaking Abstracts

10:00 am – 4:00 pm  
Exhibit Hall Open  
Poster Viewing

10:00 am – 10:30 am  
COFFEE BREAK

10:30 am – Noon  
Concurrent Abstract Sessions

Noon – 12:30 pm  
Box Lunch Pick-up

12:15 pm – 1:45 pm  
Mid-Day Symposium 1: Pushing The Limits For  
Thoracic Organ Transplantation

CHAIRS:  James B. Young, M D and  
John B. O’Connell, M D

12:15 pm  When Is Obesity A Contraindication?,  
Michael M. Givertz, M D, Brigham & Women’s Hospital,  
Boston, M assachusetts

12:26 pm  When Is History Of Drug Abuse A  
Contraindication?, Susan E. Abbey, M D, FRCPC,  
University Health Network, Toronto, Canada

12:37 pm  How Much Alcohol Is A Contraindication?,  
Luciano Potena, M D, PhD, University of Bologna, Italy

12:48 pm  Infectious Disease: Is Hepatitis A Con-  
taindication?, Jeffrey J. Teuteberg, M D, University of  
Pittsburgh/Presbyterian, Pittsburgh, Pennsylvania

12:59 pm  Can Patients With HIV Have A Transplant?,  
Margaret M. Hannan, M D, Mater Hospital, Dublin,  
Ireland

1:10 pm  When Was The Last Cigarette?, Savitri E.  
Fedson, M D, University of Chicago Hospitals, Chicago,  
Illinois

1:21 pm  The Loner, Michael G. Petty, PhD(c), RN,  
CCNS,CNS, University of M innesota Medical Center-  
Fairview, M inneapolis, M innesota

1:32 pm  The Non-Compliant, Kathleen L. Grady, PhD,  
APN, FAAN, Northwestern Memorial Hospital,  
Chicago, Illinois

12:15 pm – 1:45 pm  
Mid-Day Symposium 2: The Failing Right  
Ventricle: Mechanisms And Management

CHAIRS:  Evelyn Horn, M D and  
Teresa De M arco, M D

12:15 pm  Physiology Of Primary And Secondary RV  
Failure: Mechanistic Implications For Diagnostic  
Testing, Therapeutic Selection And Outcome Pre-  
diction, Thomas D’Salvo, M D, Vanderbilt University,  
Nashville, Tennessee

12:35 pm  Management Of Patients With PH And RV  
Failure Undergoing Anesthesia For Extrathoracic  
Surgical Procedures: Approaches To Avoid – Or  
Manage – Cardiogenic Shock, Dana M. Glothlin,  
M D, University of California, San Francisco, California

12:55 pm  Peri-Operative Management Of Patients  
With Right Ventricular Failure Undergoing Heart  
Or Lung Transplantation Or LVAD Implantation:  
Medical And Surgical Tricks-Of-The-Trade, Srinivas  
Murthy, M D, Allegheny General Hospital, Pittsburgh,  
Pennsylvania
Emerging Therapies To Treat Pulmonary Hypertension And Right Ventricular Failure: Gene Therapy, Pharmacologic Agents And Mechanical Devices, Mardi Gomberg-Maitland, MD, University of Chicago Medical Center, Chicago, Illinois

Panel Discussion

12:15 pm - 1:45 pm
Mid-Day Symposium 3: Immunological Aspects Of Engineered Heart Tissue And Cellular Replacement Therapies In Heart Failure
CHAIRS: Doris A. Taylor, PhD and Sonja Schrepfer, M D, PhD

Update On Engineered Heart Tissue, Prof. Thomas Eschenhagen, M D, University Medical Center Hamburg, Germany

Augmenting Cardiomyocyte Proliferation In The Failing Heart, Loren J. Field, PhD, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN

Immunological Aspects Of Stem-Cell Based Therapeutical Approaches, Stefan Janssens, M D, PhD, Vesalius Research Center, University of Leuven, Belgium

Panel Discussion

12:15 pm - 1:45 pm
Mid-Day Symposium 4: Update On Pediatric MCS Therapy
CHAIRS: Elizabeth Blume, M D and Roland Hetzer, M D, PhD

Anatomy And Physiology In Congenital Heart Disease Complicating MCS Device Implant, Eric Devaney, M D, University Of Michigan, Ann Arbor, Michigan

Current Device Options For Pediatric Patients And Implantation Techniques For The Single Ventricle, Michael Hubler, M D, German Heart Institute, Berlin, Germany

Update On The North American Berlin Heart Pediatric Excor® Experience: Holger W. Buchholz, M D, University Of Alberta Hospital, Edmonton, Canada

Update On The NIH PumpKIN Trial, Bartley P. Griffith, M D, University Of Maryland, Baltimore, Maryland

Panel Discussion

3:30 pm - 4:00 pm
COFFEE BREAK

4:00 pm - 5:30 pm
Concurrent Abstract Sessions

5:30 pm - 6:30 pm
Mini Oral Abstract Sessions

Infectious Diseases Council Meeting
Mechanical Circulatory Support Council Meeting
Nursing, Social Sciences and Allied Health Council Meeting
Pulmonary Hypertension Council Meeting

Friday, April 15, 2011

6:30 am - 6:30 pm
Speaker Ready Room Open

7:00 am - 5:30 pm
Registration Desk Open

7:00 am - 8:00 am
Sunrise Symposium 5: “It’s Alive!” Myocardial Recovery During LVAD Support in 2011
CHAIRS: O. Howard Frazier, M D and Steven S. L. Tsui, M D, FRCS

The Disconnect Between Cellular And Clinical Recovery: What Are We Missing?, Kenneth B. Margulies, M D, University Of Pennsylvania Health System, Philadelphia, Pennsylvania

Myocardial Recovery During LVAD Support: Pulsatile Versus Continuous Flow Devices, Thomas Krabatsch, M D, PhD, German Heart Institute, Berlin, Germany

Techniques To Facilitate Device Extraction Following Recovery: Case Presentation, Evgenij V Potapov, M D, PhD, German Heart Institute, Berlin, Germany

7:00 am - 8:00 am
Sunrise Symposium 6: Experimental Models of Lung Transplantation
CHAIRS: Daniel Kreisel, M D, PhD and Florian M. Wagner, M D

Heterotopic And Orthotopic Tracheal Transplantation, Sonja Schrepfer, M D, PhD, University Heart Center Hamburg, Germany
7:20 am  Orthotopic Lung Transplantation In The Mouse, Alexander S. Krupnick, MD, Washington University School of Medicine, St. Louis, Missouri

7:40 am  Large Animal Models Of Lung Transplantation, James S. Allan, MD, Massachusetts General Hospital, Boston, Massachusetts

7:00 am – 8:00 am  Sunrise Symposium 7: Why are Children Immunologically Different?
CHAIRS: Marc G. Schecter, MD and Melanie D. Everitt, MD

7:00 am  Developmental Immunology: How Do The Younger Patients Differ?, Simon Urschel, MD, University of Alberta, Edmonton, Canada

7:20 am  Infection Risk In The Younger Population, Lara Danziger-Isakov, MD, MPH, The Cleveland Clinic Foundation, Cleveland, Ohio

7:40 am  Exploiting The Differences In Children, Lori J. West, MD, DPhil, University of Alberta, Alberta Diabetes Institute, Edmonton, Alberta, Canada

7:00 am – 8:00 am  Sunrise Symposium 8: Pulmonary Hypertension Complicating Left Ventricular Failure: Problems And Progress
CHAIRS: Myung Park, MD and Raymond L. Benza, MD

7:00 am  Case Presentation: A 64-Year-Old Woman With Mitral Stenosis And Paroxysmal Atrial Fibrillation Complicated By Severe Pulmonary Hypertension And Scleroderma, Robert P. Frantz, MD, Mayo Clinic, Rochester, Minnesota

7:10 am  Operative Assessment And Management Of Mitral Valve Disease Complicated By Pulmonary Hypertension, Soon Park, MD, Mayo Clinic, Rochester, Minnesota

7:30 am  Case Presentation: Pulmonary Hypertension With Left Heart Failure, Veronica Franco, MD, Ohio State University, Columbus, Ohio

7:40 am  Drug Therapy For PH And LV Failure: Current Approaches, Marc Semigran, MD, Massachusetts General Hospital, Boston, Massachusetts

8:00 am – 10:00am  Plenary Session: Gazing Into the Crystal Ball – Emerging Therapy in Thoracic Transplantation
CHAIRS: Stuart W. J amieson, MB, FRCS and Paul A. Corris, MB, FRCP

8:00 am  The Future Of Immune Modulation In The Clinical Setting, David S. Wilkes, MD, Indiana University School of Medicine, Indianapolis, Indiana

8:24 am  Survivors of CHD, What Will Be Best Therapy: Transplantation Versus MCS?, Felix Berger, MD, German Heart Institute, Berlin, Germany

8:48 am  Cell Based Alternatives To MCS: Reconstruction Ahead?, Eduardo M arbán, MD, PhD, Cedars Sinai Heart Institute, Los Angeles, California

9:12 am  Engineering Lungs For Transplant: The Potential Benefits Of Ex Vivo Therapy, Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Canada

9:36 am  Lung Assist Devices. What Will Be Possible In The Clinical Setting In Five Years?, Joseph B. Zwischenberger, MD, University of Kentucky, Lexington, Kentucky

10:00 am – 10:30 am  ANNUAL BUSINESS MEETING

10:00 am – 4:00 pm  Exhibit Hall Open
Poster Viewing

10:00 am – 10:30 am  COFFEE BREAK

10:30 am – Noon  Concurrent Abstract Sessions

Noon – 12:30 pm  Box Lunch Pick-up

12:15 pm – 12:45 pm  Mid-Day Symposium 5: Palliative Care Across The Illness Trajectory
CHAIRS: Annette DeVito Dabbs, RN, PhD and James K. Kirklin, MD

12:15 pm  Introduction: Definition Of Palliative Care And Applications To Transplant, Winifred G. Teuteberg, MD, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

12:25 pm  Practical Hints In Palliative Care, Patricia A. Uber, PharmD, University of Maryland, Baltimore, Maryland

12:35 pm  Pulmonologist’s View Of Palliative Care In The Pre-Transplant Period, Martin Carby, MD, Harefield Hospital, Harefield, United Kingdom

12:45 pm  The Nurses’ View Of Palliative Care In Post-Transplant Care, Mi Kyung Song, RN, PhD, University of North Carolina at Chapel Hill, North Carolina
12:55 pm  The MCS Coordinator Perspective On Palliative Care, Annemarie Kaan, MCN, RN, St. Paul’s Hospital, Vancouver, British Columbia, Canada

1:05 pm  The Cardiologist’s View Of Palliative Care In Chronic Heart Failure Before Or After Transplantation, Savitri Fedson, MD, University of Chicago Hospitals, Chicago, Illinois

1:15 pm  Panel Discussion

12:15 pm - 1:45 pm

CHAIRS: Stuart C. Sweet, M D and Sean P. Pinney, M D

12:15 pm  United States: Mark L. Barr, MD, University of Southern California, Los Angeles, California

12:25 pm  England: John J. Dunning, FRCS, Papworth Hospital, Cambridge, United Kingdom

12:35 pm  Australia: Anne Keogh, MBBS, M D, St. Vincent’s Hospital, Sydney, Australia

12:45 pm  Spain: Nicolas Manito, M D, Hospital Universitari de Bellvitge, Barcelona, Spain

12:55 pm  Canada: Heather J. Ross, M D, M HSc, FRCP(c), Toronto General Hospital, Toronto, Canada

1:05 pm  Eurotransplant: Jacqueline M. Smits, MD, PhD, Eurotransplant International Foundation, Leiden, The Netherlands

1:15 pm  Japan: Takeshi Nakatani, M D, PhD, National Cardiovascular Center, Osaka, Japan

1:30 pm  Panel Discussion

12:15 pm - 1:45 pm
Mid-Day Symposium 7: AST At ISHLT: Lessons From Other Organs

CHAIRS: John Dark, MB, FRCS and Maryl R. Johnson, MD

12:15 pm  Emerging Pharmacologic Immunosuppression: Updates From Clinical Trials In Kidney Transplantation, Robert S. Gaston, MD, University of Alabama at Birmingham, Alabama

12:45 pm  Emerging Biologics In Organ Transplantation, Flavio Vincenti, MD, University of California San Francisco, California

1:15 pm  Lessons Learned From Transplant Patients Off Immunosuppressive Drugs, Kenneth Newell, M D, PhD, Emory Transplant Center, Atlanta, GA

ON-LINE REGISTRATION IS ENCOURAGED AND IS AVAILABLE ON THE ISHLT WEBSITE: www.ishlt.org
12:15 pm – 1:45 pm
**Mid-Day Symposium 8: Future Therapies For End-Stage Thoracic Organ Failure**

CHAIRS: Walter Weder, M.D and Robert B. Love, M.D

12:15 pm  Regeneration Of Bioartificial Airways/Lungs, Thomas K. Waddell, M.D, PhD, Toronto General Hospital, Toronto, Canada

12:45 pm  Regenerative Therapy For Pulmonary Hypertension, Duncan J. Stewart, M.D, FRCPC, St. Michael’s Hospital/University of Toronto, Canada

1:15 pm  Is There A Future For Engineered Heart And Lung?, Dons Taylor, PhD, University of Minnesota, Minneapolis, MN

12:45 pm – 1:45 pm
Junior Faculty Mentor Lunch
(pre-registration and ticket required; registration limited to 100)
Council Chairs’ Luncheon Meeting

2:00 pm – 3:30 pm
**Concurrent Abstract Sessions**

3:30 pm – 4:00 pm
COFFEE BREAK

4:00 pm – 5:30 pm
**Concurrent Abstract Sessions**

4:00 pm – 11:59 pm
Exhibit Hall Strike

5:30 pm – 6:30 pm
**Mini Oral Abstract Sessions**
Past Presidents’ Council Meeting/Reception

6:30 pm – 7:30 pm
J unior Faculty and Trainee Council Meeting

8:00 pm – 10:00 pm
PRESIDENT’S GALA RECEPTION

---

**Saturday, April 16, 2011**

6:30 am – 4:30 pm
Speaker Ready Room Open

7:00 am – 2:30 pm
Registration Desk Open

---

7:00 am – 8:00 am
**Sunrise Symposium 9: Acid-Fast, Act Fast And Not So Fast Infections: You Make The Call!**

CHAIRS: Frauke Mattner, M.D and Vincent G. Valentine, M.D

7:00 am  NTM Isolates Pre-Transplant: Colonization, Infection Or Disease?, Cecilia Chaparro, M.D, Toronto General Hospital, Toronto, Canada

7:20 am  Oops! I Didn’t See That Coming: Unexpected Finding In The Explanted Lung, Amparo Sole, M.D, University Hospital la Fe, Valencia, Spain

7:40 am  Managing Nocardiosis In Thoracic Organ Transplantation, Stanley I. Martin, M.D, Ohio State University Medical Center, Columbus, Ohio

7:00 am – 8:00 am
**Sunrise Symposium 10: Standardized M CS Guidelines: We Have Arrived**

CHAIRS: Stephanie A. Moore, M.D and Emma Birks, FRCP, PhD

7:00 am  Overview And Goals Of M CS Guidelines, Stephanie A. Moore, M.D, Massachusetts General Hospital, Boston, Massachusetts

7:10 am  Guidelines At A Glance, Jeffrey A. Morgan, M.D, Henry Ford Hospital, Detroit, Michigan

7:30 am  Implementation Impact And Future Direction Of Standardized Guidelines, Emma Birks, FRCP, PhD, University of Louisville, Kentucky

7:40 am  Question/Answer Panel:

Katherine Lietz, M.D, PhD, Yale University School of Medicine, New Haven, Connecticut
Michael G. Petty, PhD(c), RN, CCNS, CNS, University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota
Salpy V. Pamboukian, MD, M.S.PH, University of Alabama at Birmingham, Alabama
David S. Feldman, M.D, PhD, Minneapolis Heart Institute, Minneapolis, Minnesota
Martín Strueber, M.D, Hannover Medical School, Hannover, Germany
Ranjit John, M.D, University of Minnesota, Minneapolis, Minnesota

7:00 am – 8:00 am
**Sunrise Symposium 11: Challenging Patients And Creative Solutions**

CHAIRS: Kevin C. Carney, RN, CCTC and Christiane Kugler, PhD

7:00 am  Lung Transplant, Holli C. Blazey, M.SN, CRNP, Cleveland Clinic Foundation, Cleveland, Ohio
7:00 am – 8:00 am

Sunrise Symposium 14: Immunobiology For The Clinician
CHAIRS: Susan D. Moffatt-Bruce, M D, PhD and Sonja Schrepfer, M D, PhD

7:00 am Antigen Presentation And T Cells, James F. George, PhD, University of Alabama at Birmingham, Alabama

7:20 am B Cells: Antibody Production And More, Esme Dijke, PhD, University of Alberta, Edmonton, Canada

7:40 am Innate Immunity, Timothy D. Lee, PhD, Dalhousie University, Halifax, Nova Scotia, Canada

8:00 am – 9:00 am

Concurrent Abstract Sessions

9:00 am – 9:30 am
Coffee Break

9:30 am – 11:30 am

Plenary Session
CHAIRS: Jon Kobashigawa, M D and John Wallwork, FRCS

9:30 am MCS Evolution And Counter-Evolution: Can We Fool Mother Nature?, Walter P. Dembisky, M D, Sharp M emorial Hospital, San Diego, California

10:00 am Awards Presentations

10:15 am Featured Abstract

10:30 am Featured Abstract

10:45 am Choices After Age 70: Three Perspectives

10:45 am Case Presentation And Chair, Lynne W. Stevenson, M D, Brigham & Women’s Hospital, Boston, M assachusetts

11:00 am Mechanical Circulatory Support, Roland Hetzer, M D, PhD, German Heart Institute, Berlin, Germany

11:00 am Heart Transplantation, Nicholas G. Smedira, M D, Cleveland Clinic Foundation, Cleveland, Ohio

11:10 am Palliative Care – Less Is More, Heather J. Ross, M D, M HSc, FRCPC, Toronto General Hospital, Toronto, Canada

11:20 am Discussion

11:45 am – 12:45 pm

Mid-Day Symposium 9: Great Debates in Cardiac Transplant Immunosuppression
CHAIRS: Michael M. Givertz, M D and Juan F. Delgado-Jimenez, M D
Resolved: All Heart Transplant Recipients Should Receive Induction Therapy
Pro: Javier Segovia, MD, PhD, Hospital Puerta de Hierro, Madrid, Spain
Con: James C. Fang, MD, University Hospital Case Medical Center, Cleveland, Ohio

Resolved: All Heart Transplant Recipients Should Be Off Corticosteroids By Three Months Post-Transplant
Pro: David A. Baran, MD, Newark Beth Israel Medical Center, Newark, New Jersey
Con: Maria G. Crespo-Leiro, MD, Hospital Universitario A Coruña, La Coruña, Spain

Resolved: TOR Inhibitor Should Replace CNI Within The First Year After Transplant
Pro: Bruno M. L. Eiser, MD, University of Munich/Grosshadern, Munich, Germany
Con: Mandeep R. Mehra, MBBS, FACC, FACP, University Hospital Zurich, Switzerland

Acquired Von Willebrand Factor Deficiency Following VAD Implant
Evgenij V. Potapov, MD, PhD, German Heart Institute, Berlin, Germany

New Drugs For Anticoagulation
Sam Schulman, MD, FRCP, McMaster University, Hamilton, Ontario, Canada

What Is The Lower Limit Of Anticoagulation Necessary For The Current Generation Of Durable MCS Devices?
Mark S. Slaughter, MD, University Cardiothoracic Surgical Associates, Louisville, Kentucky

Case Presentation: Should Psychosocial Status Be A Contraindication To Heart Transplant?
Tajinder P. Singh, MD, Children’s Hospital of Boston, MA

Case Presentation: Would You Accept This Patient For Heart Transplant?
David N. Rosenthal, MD, Stanford University, Palo Alto, California

Case Presentation: Would You Do A Third Lung Transplant?
Christian Benden, MD, University Hospital Zurich, Switzerland

A $100 Discount Off The Registration Fee Is Offered To Those Who Register On Or Before March 2, 2011.
**Mid-Day Symposium 12: Quandary At The Lung Transplant Board Meeting**

CHAIRS: Selim M. Arcasoy, M.D. and Peter M. Hopkins, FRACP

**11:45 am** A Patient With Idiopathic Pulmonary Fibrosis: Single Versus Bilateral Lung Transplantation? A Balanced Review Of Pros And Cons Of Each Procedure In This Disease, David J. Lederer, M.D., Columbia University, New York, New York

**12:15 pm** How Old Is Too Old For Lung Transplantation? Recipient And Donor Selection – A Review Of The Impact Of Recipient And Donor Age In Post-Transplant Outcomes, Daniel F. Dilling, M.D., Loyola University Medical Center, Maywood, Illinois

---

**Mid-Day Symposium 13: Clinical Controversies in Pulmonary Hypertension: To Treat Or Not To Treat? That Is The Question**

CHAIRS: Robert J. Schilz, DO, PhD and Ivan Robbins, M.D.

**11:45 am** How To Treat Class III PAH Patients: Stepwise Treatment Combining Oral And Inhaled Therapies Is The Best Approach, Anne Keogh, MBBS, MD, St. Vincent’s Hospital, Sydney, Australia

**12:00 pm** How To Treat Class III PAH Patients: Continuous Prostanoids Should Be The First Line Of Treatment, Harrison W. Farber, M.D., Boston University School of Medicine, Boston, Massachusetts

**12:15 pm** Exercise-Induced PH: Does It Exist? Should We Treat It? A Case Based Discussion, Myung Park, MD, University of Maryland, Baltimore, MD

**12:30 pm** Pulmonary Hypertension And Interstitial Lung Disease: Should Therapies Be Directed At Pulmonary Hypertension? A Case Based Discussion, Steven D. Nathan, M.D., Fairfax Inova Hospital, Falls Church, Virginia

---

**Mid-Day Symposium 14: What Is It? Intriguing Cases In Heart Transplantation**

CHAIRS: Mario Deng, MD and Margaret M. Burke, FRCPath

**11:45 am** - **12:45 pm**

Case Presenters:

- Patrick Bruneval, M.D., Hospital European Georges Pompidou, Paris, France
- Desley Neil, BM edSc, M.B., University of Birmingham, United Kingdom
- Dylan V. Miller, M.D., Intermountain Central Lab, Murray, Utah
- Marc K. Halushka, M.D., PhD, Johns Hopkins Hospital, Baltimore, Maryland
- Dylan V. Miller, MD, Intermountain Central Lab, Murray, Utah
- Marc K. Halushka, M.D., PhD, Johns Hopkins Hospital, Baltimore, Maryland
- M arcos Garza, MD, University of Minnesota, Minneapolis, Minnesota
- John Wallwork, FRCS, Papworth Hospital, Cambridge, United Kingdom

---

**Closing Plenary Session**

CHAIRS: Stuart C. Sweet, M.D. and Lori J. West, M.D., DPhil

**2:15 pm** Keynote Plenary Lecture: Proteomics/Novel Diagnostics In Transplantation, Daniel R. Salomon, M.D., The Scripps Research Institute, La Jolla, California

**2:45 pm** ISHLT, TTS And W HO: An Emerging International Public Policy Initiative For Promoting Organ Donation, Francis L. Delmonico, M.D., Massachusetts General Hospital, Boston, MA

**3:05 pm** What’s Hot/What’s Cool

- Heart Transplantation and Clinical Heart Failure, Mendip R. Mehra, M.BBS, FACC, FACP, University of Maryland, Baltimore, Maryland
- Lung Transplantation, Allan R. Glanville, M.D., FRACP, St. Vincent’s Hospital, Sydney, Australia
- Mechanical Circulatory Support, Francis D. Pagani, M.D., PhD, University of Michigan Health System, Ann Arbor, Michigan
- Basic Science and Immunobiology, Stephan M. Ensminger, M.D., PhD, University of Erlangen-Nurnberg, Erlangen, Germany

**4:05 pm** Discussion

**4:10 pm** Debate: Supersize Me: Obesity Is NOT A Contraindication To Thoracic Replacement Therapy

**Pro:** Marshall Hertz, M.D., University of Minnesota, Minneapolis, Minnesota

**Con:** John Wallwork, FRCS, Papworth Hospital, Cambridge, United Kingdom

---

**ISHLT Board of Directors Meeting**

**4:45 pm** - **9:30 pm**

**11:45 am** - **1:00 pm**

Council Reports to the Board and Membership

**1:00 pm** - **2:00 pm**

Concurrent Abstract Sessions

**2:00 pm** - **2:15 pm**

Coffee Break

**2:15 pm** - **4:40 pm**

Closing Plenary Session

---

**ISHLT 31st Annual Meeting - Scientific Program**

**Saturday**

**11:45 am - 12:45 pm**

**Mid-Day Symposium 12: Quandary At The Lung Transplant Board Meeting**

**11:45 am - 12:45 pm**

**Mid-Day Symposium 13: Clinical Controversies in Pulmonary Hypertension: To Treat Or Not To Treat? That Is The Question**

**11:45 am - 12:45 pm**

**Mid-Day Symposium 14: What Is It? Intriguing Cases In Heart Transplantation**

**11:45 am - 12:45 pm**

**Mid-Day Symposium 12: Quandary At The Lung Transplant Board Meeting**

**11:45 am - 12:45 pm**

**Mid-Day Symposium 13: Clinical Controversies in Pulmonary Hypertension: To Treat Or Not To Treat? That Is The Question**

**11:45 am - 12:45 pm**

**Mid-Day Symposium 14: What Is It? Intriguing Cases In Heart Transplantation**

---

**ISHLT Board of Directors Meeting**

---

**ISHLT 31st Annual Meeting - Scientific Program**

**Saturday**

**11:45 am - 12:45 pm**

**Mid-Day Symposium 12: Quandary At The Lung Transplant Board Meeting**

**11:45 am - 12:45 pm**

**Mid-Day Symposium 13: Clinical Controversies in Pulmonary Hypertension: To Treat Or Not To Treat? That Is The Question**

**11:45 am - 12:45 pm**

**Mid-Day Symposium 14: What Is It? Intriguing Cases In Heart Transplantation**

---

**ISHLT Board of Directors Meeting**

---

**ISHLT 31st Annual Meeting - Scientific Program**

**Saturday**

**11:45 am - 12:45 pm**

**Mid-Day Symposium 12: Quandary At The Lung Transplant Board Meeting**

**11:45 am - 12:45 pm**

**Mid-Day Symposium 13: Clinical Controversies in Pulmonary Hypertension: To Treat Or Not To Treat? That Is The Question**

**11:45 am - 12:45 pm**

**Mid-Day Symposium 14: What Is It? Intriguing Cases In Heart Transplantation**

---

**ISHLT Board of Directors Meeting**
In response to goals developed at the ISHLT 2006-2007 Strategic Planning Meeting, the Society is pleased to announce the establishment of the ishlt academy. The ishlt academy draws on the wealth of experience and expertise within the society to deliver high quality educational experiences with the goal of enabling our members to improve and maintain the highest possible standards in the care of patients with advanced heart and lung disease and those undergoing heart or lung transplantation.

The ishlt academy represents the ‘brand name’ that will be associated with the educational opportunities offered by the ISHLT to its members and interested non-members. The purpose of the ishlt academy is to develop an enduring resource of education in core competencies in the field of cardiopulmonary transplantation, mechanical and biological support of the failing heart, advanced lung disease (including pulmonary vascular disease) and cell replacement therapy. These educational endeavors will complement the ISHLT’s existing activities in the promulgation of new science, registry analysis, guideline statements and monograph series as a consolidated activity designed to train and educate young clinicians, trainees and those looking for a refresher course in clinical practice mandates in the field.

The opportunities provided by the ishlt academy will be multimodality and multi-disciplinary and will be guided by the identified educational needs or ‘practice gaps’ of ISHLT members. When available, core curriculum and competency documents for different disciplines within the society will guide content of ishlt academy activities. The activities of the academy will run throughout the societies interface with its members with material provided in written format via articles in the Journal of Heart and Lung Transplantation, via the ISHLT Monograph series and via educational meetings. Select educational activities included within the Annual Meeting will also carry the ishlt academy brand and will run in concert with the scientific content of the Annual Meeting.

The day prior to the 2011 Annual Meeting, we will be conducting the second ishlt academy: Core Competencies in Lung Transplantation. Program information follows. You may register for this course via the Annual Meeting registration form. Attendance at the Annual Meeting is NOT required in order to register for the ishlt academy.
ishlt academy: *Core Competencies In Lung Transplantation*
2:00 pm Tuesday, April 12 - 12:30 pm Wednesday, April 13, 2011

**CHAIRS:**
Christopher Wigfield, M D, FRCS
John Dark, FRCS
David Weill, M D
Lianne Singer, M D

The *ishlt academy core competencies in lung transplantation* will provide a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of lung transplantation. The course consists of focused presentations with an emphasis on clinical practice. All lectures will be delivered by internationally recognized experts in the field. Related topics will be discussed in Question and Answer sessions following each lecture. The course will be interactive and assist participants with more detailed individual review. This course is designed to be of benefit for both seasoned clinicians and allied professionals practicing in the field, but is primarily arranged for current trainee physicians, Fellows and attending providers in the early stages of their careers.

The course is based on the ISHLT Lung Transplantation Core Competency Curriculum (ISHLT LTx CCC), which will be available on the ISHLT web site in December, 2010. Extensive referencing in that document should assist selective individual study and review of published evidence for each topic. The ISHLT LTx CCC document also includes active hyperlinks and related multi-media resources. The core curriculum also serves hospital programs providing lung transplantation with a tool to review their standards of care, develop protocols and implement current guidelines established in lung transplantation.

The faculty for this course consists of internationally recognized leaders in each subspecialty and the educational workforce of the Pulmonary Council is confident this course will be most comprehensive and valuable for practitioners in the field of lung transplantation.
Accreditation
The ishlt academy: core competencies in lung transplantation has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this educational activity for a maximum of 9.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Educational Goals
The educational goals of this activity are to provide a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of lung transplantation. The course consists of focused presentations with an emphasis on clinical practice.

Target Audience
This course is designed to be of benefit for both seasoned clinicians and allied professionals practicing in the field, but is primarily arranged for current trainee physicians, Fellows and attending providers in the early stages of their careers.

Faculty
Selim Arcasoy, MD, Columbia University, New York, New York
Gerald J. Berry, M D, Stanford University, Palo Alto, CA
Annette Boehler, M D, University Hospital Zurich, Switzerland
Paul Corris, M B FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
John Dark, M B FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Duane Davis, M D, Duke University Medical Center, Durham, North Carolina
Edward R. Garrity, J r, M D, University of Chicago Medical Center, Chicago, IL
Kate Gould, FRCPath, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Marshall I. Hertz, M D, University of Minnesota, Minneapolis, Minnesota
Shaf Keshavjee, M D, FRCSC, Toronto General Hospital, Toronto, Canada
Robert B. Love, M D, Loyola University Medical Center, Maywood, Illinois
Martha L. Mooney, M D, Sentara Norfolk Transplant Center/ EVM S, Norfolk, Virginia
Gregory I. Snell, FRACP M BB, Alfred Hospital, Melbourne, Australia
Susan Stewart, FRCPath, Papworth Hospital, Cambridge, United Kingdom
Walter Weder, M D, University Hospital Zurich, Switzerland
Christopher H. Wigfield, M D, FRCS, Loyola University Medical Center, Maywood, Illinois
Tuesday, April 12, 2011
1:30 pm  Registration
2:00 pm  Welcome and Introductions
2:15 pm  Introduction and Overview of Lung Transplantation
   1. Background and History of Lung Transplantation and Challenges in Lung Transplantation
   2. Programs, Databases, ISHLT Registry and Outcomes in Lung Transplantation
3:00 pm  Question and Answer Session
3:15 pm  Evaluation and Management of the Lung Transplant Candidate
   1. Indications for Lung Transplantation and Referral Guidelines
   2. Transplant Candidate Evaluation and Ongoing Management
4:15 pm  Question and Answer Session
4:30 pm  BREAK
4:45 pm  Lung Allograft Donation and Procurement
   1. Background and Donor Definitions, Lung Donor Offer and Evaluation Process
   2. Lung Allograft Procurement Principles, Additional Lung Donor Options & Future Directions
5:45 pm  Question and Answer Session
6:00 pm  DINNER BREAK
   ISHLT-sponsored Faculty Dinner, Delegates on own
7:30 pm  Lung Transplantation: Surgical and Post-Operative Management
   1. Surgical Options and Procedural Issues in Lung Transplantation
   2. Surgical Complications & Post-OP Management after Lung Transplantation
8:30 pm  Question and Answer Session
8:45 pm  Panel Discussion, Review of Day 1
9:00 pm  Adjourn

Wednesday, April 13, 2011
7:30 am  Rejection After Lung Transplantation and Immunosuppression Protocols
   1. Acute Cellular Rejection, The Sensitized Recipient and Immunosuppression Regimens Post Lung Transplantation
   2. Humoral or Antibody-Mediated Rejection, Medical Complications Post Transplantation and Bronchiolitis Obliterans Syndrome
8:45 am  Question and Answer Session
9:00 am  Lung Transplantation Pathology
   1. Specimen Adequacy and Handling
   2. Preservation Injury and other causes of Early Graft Failure
   3. Pathology of Acute Cellular Rejection (ACR)
   4. Histopathological Mimics of ACR including Infection
   5. Lymphocytic Bronchiolitis/ Bronchitis
   6. Chronic Airway Rejection
   7. Acute Antibody Mediated Rejection (AMR)
   8. Recurrence of Primary Pathology
9:45 am  Question and Answer Session
10:00 am  BREAK
10:15 am  Infections After Lung Transplantation
   1. Immune Response to Infection
   2. Significance of Infections in the Donor
   3. Impaired Physiology in the Allograft and Impact on Infection
   4. Overview and Timeline of Infections After Lung Transplantation
   5. Diagnosis, Prophylaxis & Management of Early Post-Transplant Infections
   6. Diagnosis, Prophylaxis & Management of Later Infections
   7. Non-Infectious Allograft Sequelae of Infectious Pathogens
   8. Immune Monitoring and Infection
11:00 am  Question and Answer Session
           ISHLT-sponsored Faculty Dinner
11:15 am  Case Discussions and Panel Discussion
   1. Case Discussion; Candidate for LTx Evaluation & Wait List Considerations
   2. Case Discussion; Donor Decision Process and Procurement Strategies
   3. Case Discussion; ACR Differential Diagnosis & Management
   4. Case Discussion; Late Infection Work up and PTLD Diagnosis
Noon  Course Summary and Adjourn
REGISTRATION FORM

IMPORTANT: See reverse side of this form for instructions and refund/registration policies.

ON-LINE REGISTRATION IS ENCOURAGED AND IS AVAILABLE ON THE ISHLT WEBSITE: www.ishlt.org

Last Name: ____________________________ First Name: ____________________________ Middle Initial: _____

Credential (MD, RN, etc.): ____________________________ Nickname for badge (if desired): ____________________________

Institution/ Organization Name for Inclusion on Badge: ____________________________________________________________

Preferred Mailing Address. Please indicate if this is a home or business address:  

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Home</td>
<td>Business</td>
<td></td>
</tr>
</tbody>
</table>

Mailing Address: ____________________________________________________________

City: ____________________________ State: ______ Postal Code: __________ Country: ____________________________

Telephone: ____________________________ Fax: ____________________________

Email: ____________________________________________________________

---

**SCIENTIFIC SESSION REGISTRATION**

<table>
<thead>
<tr>
<th></th>
<th>Postmarked on or before March 2</th>
<th>Postmarked after March 2</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular Member</td>
<td>$695</td>
<td>$795</td>
<td>$</td>
</tr>
<tr>
<td>Regular Non-Member †</td>
<td>$970</td>
<td>$1070</td>
<td>$</td>
</tr>
<tr>
<td>Allied Health Member *</td>
<td>$450</td>
<td>$550</td>
<td>$</td>
</tr>
<tr>
<td>Allied Health Non-Member †</td>
<td>$725</td>
<td>$825</td>
<td>$</td>
</tr>
<tr>
<td>Student/ Resident Member *</td>
<td>$350</td>
<td>$450</td>
<td>$</td>
</tr>
<tr>
<td>Student/ Resident Non-Member †</td>
<td>$475</td>
<td>$575</td>
<td>$</td>
</tr>
</tbody>
</table>

* See instruction #8

† Non-member registration prior to March 2 includes membership in the Society through December 31, 2011.

☐ Please check here if you wish to decline this membership offer (no refund or reduction of fee).

---

**GALA RECEPTION** (1 ticket is included with your registration fee)

Additional Tickets to Gala Reception for spouses/guests: ____________ # of tickets x $75 $ ____________

---

**JUNIOR FACULTY MENTOR LUNCH**

☐ $15  ☐ $15 $ ____________

Registration is limited to the first 100 student/resident/fellow members of ISHLT who are registered for the meeting.

---

**BOX LUNCHES**

<table>
<thead>
<tr>
<th>Day</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
<th>Saturday</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price</td>
<td>$15</td>
<td>$15</td>
<td>$15</td>
<td>$15</td>
</tr>
</tbody>
</table>

$ ____________

---

**CORE COMPETENCIES IN LUNG TRANSPLANTATION**

Limited to the first 150 registrants.

<table>
<thead>
<tr>
<th></th>
<th>Member</th>
<th>Non-Member</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$200</td>
<td>$275</td>
</tr>
<tr>
<td></td>
<td>$250</td>
<td>$325</td>
</tr>
</tbody>
</table>

$ ____________

**SUBTOTAL:** $ ____________

---

**PAYMENT** See instruction #10 for Wire Transfer Instructions. Full payment in US funds only must accompany your registration form.

Checks must be made payable to ISHLT and must be drawn on a US bank. If you prefer to pay by credit card, please complete the following and either mail or fax (To avoid duplicate charges do not mail AND fax your form.)

Credit Card: ☐ VISA ☐ Mastercard ☐ American Express  

Card Holder Signature: ____________________________________________  

Card Number: ____________________________  

CSC Code:* ____________________________  

Expiration Date: ____________________________  

*CSC (Credit Card Security Code is the 3 digit code on the back of MC/ VISA and 4 digit code on front of AMEX.)

Card Holder Billing Zip/Postal Code: ____________________________ (required)

**IMPORTANT DO NOT include payment for your hotel deposit with your registration payment.**

Send this form and payment in full to: ISHLT, 14673 Midway Road, Suite 200, Addison, TX 75001, or fax to 972-490-9499
REGISTRATION POLICIES/INSTRUCTIONS FOR COMPLETING THE REGISTRATION FORM:

1. The registration fee includes admittance into the Sunrise Symposia, Satellite Symposia, Plenary Sessions, Concurrent Sessions, Mid-Day Symposia, Mini Oral Sessions, Poster Session and the Exhibit Hall, as well as coffee breaks each day, the reception on Wednesday evening and one ticket to the Gala Reception on Friday evening.

2. You must be registered for the Scientific Sessions in order to attend the Satellite, Sunrise and/or Mid-Day Symposia.

3. **DO NOT** include payment for your hotel deposit with your registration payment. Payments that include such will be returned to you.

4. For those who register prior to March 2, the non-member registration fee includes membership in the Society from the date of registration through December 31, 2011. You will be required to complete a membership application in order to activate your membership. Please mark the box provided if you do not wish to accept the offer of membership. Declining the offer will not result in a reduction of the non-member registration fee.

5. **DO NOT** fax your registration form if you are paying by check or bank draft. Registration forms received without payment will not be processed.

6. **Individuals whose registration and payment are not RECEIVED by March 2, 2011 must register on-site.**
   Registration fees are determined by the date when payment in full is postmarked/ faxed. Registration forms sent without payment in full or with invalid credit card information are subject to the registration fee in effect at the time payment in full is postmarked/ faxed or when the correct credit card information is provided.

7. Cancellations must be submitted in writing in order to qualify for any refund. For written cancellation notices RECEIVED by March 2, 2011, a full refund of the scientific session fees paid will be given, less a $75 handling fee. **For written cancellation notices received after March 2, 2011, no refund of any fees will be given.**

8. *The Allied Health rate is available only to nurses, transplant coordinators, pharmacists, social workers, perfusionists and engineers. The following are excluded: MDs, PhDs, individuals with doctorates, their equivalents and pharmaceutical and device company employees/ consultants and must register at the full member or non-member rate. Non-member allied health registrants must include with their registration forms a letter signed by the chief/ dean of their transplant program verifying their employment and allied health status. Forms submitted without this letter will not be processed.*

   *The Student/ Resident registration rate is available only to residents, fellows, medical students, nursing students and graduate students. Non-member student/ resident registrants must include with their registration forms a letter signed by the chief/ dean of their program verifying their training status. Forms submitted without this letter will not be processed.*

9. Full payment in **US funds only** must accompany your registration. Checks must be made payable to ISHLT and must be drawn on a US bank. All bank fees incurred for the processing of your payment will be billed to you.

10. **Wire Transfers must be received by March 2, 2011. There will be an additional fee for wire transfers in the amount of $35 which must be paid by the sender. Please request bank/ wire transfer instructions by emailing leeann.mills@ishlt.org.**

11. Travel agencies/ sponsoring agencies will not be allowed to pick up multiple registrants’ name badges. Only the person registered for the meeting may pick up his/ her name badge. **No Exceptions.**

QUESTIONS???
Call the ISHLT Headquarters Office at 972-490-9495, or email us at meetings@ishlt.org, or fax us at 972-490-9499.
ISHLT HOUSING FORM:

Reservations may be made using this Housing Form or by telephone by calling Hilton Reservations toll free at 800-445-8667 or on the Hilton San Diego Bayfront Hotel reservation link:

Please use one form to reserve one room. You may photocopy this form to reserve additional rooms. Reservations forms must be received by the Hilton San Diego Bayfront Hotel with one night’s deposit no later than Monday, March 12, 2011 or until the block is sold out. No more than 5 rooms may be reserved in the name of any one individual. If you require more than 5 rooms, please contact the ISHLT Headquarters office for a group reservation form.

1) Name of Hotel Guest:

<table>
<thead>
<tr>
<th>LAST NAME</th>
<th>FIRST NAME</th>
<th>MIDDLE INITIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Arrival Date: ____________________________  Departure Date: ____________________________

Institution/ Company (required): ____________________________

Address: _____________________________________________________________

City: ____________________________  State: ____________  Country: ____________________________  Post Code: ____________

Phone: ____________________________  Fax: ____________________________

Email: ____________________________  HHONORS #: ____________________________

Requests: ____________________________

2) Do you require:

- [ ] Smoking Room
- [ ] Non-Smoking Room
- [ ] Special Accommodations: ____________________________________________

3) Room Type:

- [ ] Single/ Double  $262

4) Preferred Bed:

- [ ] King Bed
- [ ] Two Double Beds

5) Please list below any individuals who will be accompanying you and staying in the same room:

<table>
<thead>
<tr>
<th>Names of Occupants Other Than Yourself</th>
<th>Arrival Date</th>
<th>Departure Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Roommate #1: _____________________________________________________________

Roommate #2: _____________________________________________________________

Roommate #3: _____________________________________________________________

6) All reservations must be secured with a deposit in the amount of one night’s lodging and tax. Reservations submitted without a deposit will not be processed.

7) Deposits may be made via credit card or check. Checks must be made payable to the Hilton San Diego Bayfront Hotel and must be drawn on a US Bank. If you prefer to pay by credit card, please complete the following:

Credit Card:  [ ] VISA  [ ] Mastercard  [ ] American Express  [ ] Discover  [ ] Diners Club

Card Number: ____________________________  Expiration Date: ____________________________

Card Holder Signature: ____________________________  Card Holder Name: ____________________________


Cancellation Policy: Notice of cancellation of reservations must be made 7 days in advance of the reservation arrival date or the deposit will be forfeited.
HILTON SAN DIEGO BAYFRONT HOTEL • SAN DIEGO, CA, USA

HILTON RESERVATIONS:
TOLL FREE 1-800-445-8667
2010-2011 BOARD OF DIRECTORS

John Dark, MB, FRCS, President
Lori J. West, MD, DPhil, President-Elect
James K. Kirklin, MD, Past-President
Duane Davis, MD, Secretary Treasurer
Raymond L. Benza, MD, Director
Susan M. Chernenko, RN, MN, NP, Director
Maria G. Crespo-Leiro, MD, Director
James F. George, PhD, Director
Allan R. Glanville, MD, FRACP, Director
Jayan Parameshwar, FRCP, Director
Patricia A. Uber, PharmD, Director
J. David Vega, MD, Director
Geert M. Verleden, MD, PhD, Director
Florian M. Wagner, MD, Director
Andreas O. Zuckermann, MD, Director

EX OFFICIO BOARD MEMBERS

Mandeep R. Mehra, MD, Editor,
Journal of Heart and Lung Transplantation
Marshall I. Hertz, MD,
Transplant Registry Medical Director
Richard N. Pierson, III, MD,
2011 Scientific Program Chair
Heather Ross, MD,
Development Committee Chair
Amanda W. Rowe,
ISHLT Executive Director

STAFF

Amanda W. Rowe,
Executive Director
Phyllis Glenn,
Director of Membership Services
Lisa A. Edwards,
Director of Meetings
Lee Ann Mills,
Director of Operations
Susie Newton,
Administrative Assistant
Future ISHLT Annual Meetings

2012
32nd ISHLT Annual Meeting and Scientific Sessions
Convention Center, Prague, Czech Republic
April 18 – 21

2013
33rd ISHLT Annual Meeting and Scientific Sessions
Palais des Congrès de Montréal, Canada
April 24 – 27